Coronavirus (COVID-19) Infection in Pregnancy

Information for healthcare professionals

Version 13: Published Friday 19 February 2021
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary of updates</td>
<td>3</td>
</tr>
<tr>
<td>1 Purpose and scope</td>
<td>4–16</td>
</tr>
<tr>
<td>2 Antenatal care during the COVID-19 pandemic</td>
<td>17–27</td>
</tr>
<tr>
<td>3 Venous thromboembolism prevention</td>
<td>28–30</td>
</tr>
<tr>
<td>4 Labour and birth during the COVID-19 pandemic</td>
<td>31–42</td>
</tr>
<tr>
<td>5 Managing clinical deterioration during the COVID-19 pandemic</td>
<td>43–51</td>
</tr>
<tr>
<td>6 Postnatal care</td>
<td>52–56</td>
</tr>
<tr>
<td>7 Acknowledgments</td>
<td>57</td>
</tr>
<tr>
<td>8 Appendix I: Summary of previous updates</td>
<td>59–73</td>
</tr>
<tr>
<td>9 Appendix II: Key considerations when caring for symptomatic women</td>
<td>74–76</td>
</tr>
<tr>
<td>with suspected/confirmed COVID-19</td>
<td></td>
</tr>
<tr>
<td>10 Appendix III: Full description of guidance development methods</td>
<td>77</td>
</tr>
<tr>
<td>11 Appendix IV: Key studies summary on the effect of COVID-19 on</td>
<td>78–82</td>
</tr>
<tr>
<td>pregnancy and maternal outcomes</td>
<td></td>
</tr>
<tr>
<td>12 Appendix V: Example of a telephone triage tool for symptomatic</td>
<td>83</td>
</tr>
<tr>
<td>women with suspected or confirmed COVID-19</td>
<td></td>
</tr>
<tr>
<td>13 Appendix VI: Example of a maternity escalation plan for women</td>
<td>84</td>
</tr>
<tr>
<td>with suspected or confirmed COVID-19</td>
<td></td>
</tr>
<tr>
<td>14 References</td>
<td>85–97</td>
</tr>
</tbody>
</table>
Summary of updates

Previous updates have been summarised in Appendix 1. New updates for this version of the guideline are summarised here.

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Summary of changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>18.02.21</td>
<td><strong>Throughout:</strong> Comprehensive editorial review resulting in rewording and minor changes.</td>
</tr>
<tr>
<td>13</td>
<td>18.02.21</td>
<td><strong>Throughout:</strong> New evidence added to most sections to support or update existing conclusions or advice.</td>
</tr>
<tr>
<td>13</td>
<td>18.02.21</td>
<td><strong>1.4 New section added:</strong> Vaccination against COVID-19</td>
</tr>
<tr>
<td>13</td>
<td>18.02.21</td>
<td><strong>1.5:</strong> Comprehensively updated including new evidence, key findings, new sections on the frequency of severe illness in pregnant women, data from the UK comparing pregnant and non-pregnant women, data from international studies comparing pregnant and non-pregnant women and insertion of tables in appendix summarising studies.</td>
</tr>
<tr>
<td>13</td>
<td>18.02.21</td>
<td><strong>Sections 2 and 6 updated:</strong> to signpost to guidance documents to assist maternity units with changes to antenatal and postnatal care.</td>
</tr>
<tr>
<td>13</td>
<td>18.02.21</td>
<td><strong>New appendices</strong> added and updated to reflect changes to document.</td>
</tr>
</tbody>
</table>
I. Purpose and scope
1. Purpose and scope

This document aims to provide guidance to healthcare professionals who care for pregnant women during the COVID-19 pandemic. It is not intended to replace existing clinical guidelines, but to act as a supplement with additional advice on how to implement standard practice during this time.

The advice in this document is provided as a resource for UK healthcare professionals based on a combination of available evidence, good practice and expert consensus opinion. The priorities are:

(i) The reduction of transmission of SARS-CoV-2 to pregnant women, their family members and healthcare workers.

(ii) The provision of safe, personalised and woman-centred care during pregnancy, birth and the early postnatal period, during the COVID-19 pandemic.

(iii) The provision of safe, personalised and woman-centred care to pregnant and postnatal women with suspected or confirmed COVID-19.

This is very much an evolving situation requiring this guidance to be a living document that is under regular review and updated as new information and evidence emerges. Updated advice and information will be published in the Coronavirus (COVID-19), pregnancy and women’s health section of the Royal College of Obstetricians and Gynaecologists (RCOG) website.

Information for pregnant women and their families is available in question and answer format, with accompanying videos in some cases, on the RCOG and Royal College of Midwives (RCM) COVID-19 hubs.

1.1 Identification and assessment of evidence

This guidance has been developed by a multidisciplinary group using the best available evidence retrieved by weekly literature reviews undertaken by a member of the RCOG Library team.

Owing to the relatively recent emergence of COVID-19 and the rapidly evolving nature of the pandemic, there is a lack of high-quality evidence. Using a conventional grading system for guideline development, such as SIGN, many of the studies would be classed as level 3 or 4 (non-analytical studies, e.g. case series/reports), with a few studies being classed as level 2 (systematic reviews of cohort studies). Much of the advice based on this evidence would therefore be graded D, and in some cases, graded as good practice points based on expert opinion. Furthermore, where randomised trials have been undertaken, such as to investigate therapeutic interventions in severe COVID-19, most of the trial participants were not pregnant. Healthcare providers, women and their families are advised to be aware of the low-quality evidence on which the advice is given when using this guidance to assist decision making.
For a more detailed description of the methods used to develop this guidance please see Appendix III.

1.2 Epidemiology

SARS-CoV-2 is the strain of coronavirus which causes COVID-19. It was first identified in Wuhan City, China, towards the end of 2019. Other human coronavirus (HCoV) infections include HCoV 229E, NL63, OC43 and HKU1, which usually cause mild to moderate upper respiratory tract illnesses, like the common cold, Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). The diagnosis of COVID-19 can be made based on symptoms and known exposure, or simply from a positive test for SARS-CoV-2 even in the absence of any symptoms. COVID-19 can therefore be symptomatic or asymptomatic.

The World Health Organization (WHO) publishes a weekly international situation report with an additional Situation Dashboard to provide information for individual countries. The total number of confirmed cases in the UK is published by the Department of Health and Social Care (DHSC), and is available in a visual dashboard.

For the most up-to-date advice please refer to health protection agency websites: for England, Wales, Scotland and Northern Ireland. Public Health England (PHE) and Public Health Scotland (PHS) have been cited throughout this document; specific guidance from the other areas of the UK will be updated as they become available.

1.3 Transmission

Most global cases of COVID-19 have evidence of human-to-human transmission. This virus can be readily isolated from respiratory droplets or secretions, faeces and fomites (objects). Transmission of the virus is known to occur most often through close contact with an infected person or from contaminated surfaces.

With regard to vertical transmission (transmission from woman to her baby antenatally or intrapartum), evidence now suggests that if vertical transmission does occur, it is uncommon. If it does occur, it appears to not be affected by mode of birth, delayed cord clamping, skin-to-skin contact, method of feeding or whether the woman and baby stay together (rooming in).

1.4 Vaccination against COVID-19

The first vaccine against COVID-19 was approved for use in the UK on the 2 December 2020, after a review by the Medicines and Healthcare products Regulatory Agency (MHRA). Since then, other vaccines have been approved and a national vaccination programme is underway. None of the vaccines have undergone specific clinical trials in pregnant women.

The Joint Committee on Vaccination and Immunisation (JCVI) published updated advice on the 30 December 2020 and confirmed the available data do not indicate any safety concerns
or harm to pregnancy, and vaccination in pregnancy should be considered where the risk of exposure to SARS-CoV-2 infection is high or cannot be avoided. Furthermore, the JCVI stated that vaccination should be considered where the woman has an underlying condition that puts her at very high risk of serious complications of COVID-19. Similar advice was issued for breastfeeding women.

Updated information for women and healthcare professionals on vaccination during pregnancy or while breastfeeding is available on the RCOG website.

1.5 Effect of COVID-19 on pregnant women

Pregnant women do not appear more likely to contract the infection than the general population.12

1.5.1 Symptoms of COVID-19 in pregnant women

The majority of pregnant women who are infected with SARS-CoV-2 will be asymptomatic: the PregCOV-19 Living Systematic Review13 reporting on universal screening in pregnancy found an estimated 74% (95% CI 51–93) of women were asymptomatic, while another study14 from the USA reported that 86% of women who were admitted in labour and who tested positive for SARS-CoV-2 were asymptomatic.

Most symptomatic women experience only mild or moderate cold/flu-like symptoms.15 The PregCOV-19 systematic review13 has so far included over 64 000 pregnant women worldwide with suspected or confirmed COVID-19 (reported prior to 29 November 2020). In this review, the most common symptoms of COVID-19 in pregnant women were cough (41%) and fever (40%). Less frequent symptoms were dyspnoea (21%), myalgia (19%), loss of sense of taste (14%) and diarrhoea (8%). Pregnant women with COVID-19 were less likely to have fever or myalgia than non-pregnant women of the same age. The PRIORITY (Pregnancy CoRonavirus Outcomes RegIsTry) study,16 an ongoing prospective cohort study of pregnant women from the United States, found the most prevalent first symptoms in infected women were cough (20%), sore throat (16%), myalgia (12%) and fever (12%). In this group of 594 symptomatic women, one-quarter had persistent symptoms 8 or more weeks after onset.

At present, it is unclear whether pregnancy will impact on the proportion of women who develop prolonged signs and symptoms after an acute SARS-CoV-2 infection, (so-called ‘long COVID’ or post COVID-19 condition). NICE has produced a rapid guideline outlining the care of individuals who develop long-term effects of COVID-19.13,17

1.5.2 Severe illness with COVID-19 in pregnant women

**Key findings**

- More than two-thirds of pregnant women with COVID-19 are asymptomatic.
Compared to non-pregnant women with COVID-19, pregnant women with COVID-19:

- have higher rates of intensive care unit (ICU) admission; this may reflect a lower threshold for admission to ICU, rather than more severe disease.
- are not at increased risk of death from COVID-19, according to the largest systematic review.
- were however found in more recent data from the USA and Mexico to have a slightly higher risk of death in these specific national healthcare settings.

Compared to pregnant women without COVID-19, pregnant women with symptomatic COVID-19 requiring hospitalisation have overall worse maternal outcomes, including an increased risk of death, although that risk remains very low (the UK maternal mortality rate from COVID-19 is 2.2 per 100 000 maternities).

### 1.5.2.1 Frequency of severe illness in pregnant women

**COVID-19** ranges from asymptomatic infection, through to mild disease (no evidence of pneumonia or hypoxia), moderate disease (viral pneumonia), severe disease (severe pneumonia, e.g. with SpO2 below 90% on room air) and critical disease (Acute Respiratory Distress Syndrome [ARDS], sepsis, septic shock, or complications such pulmonary embolism or acute coronary syndrome).

Severe illness, such as that requiring ICU admission, is relatively uncommon in women of reproductive age, but can occur: During the initial wave of the pandemic, there were case reports and case series of women with severe COVID-19 infection at the time of birth who have required ventilation and extracorporeal membrane oxygenation (ECMO), and of maternal death. In the PregCOV-19 Living Systematic Review Consortium analysis, 73/11 580 women with confirmed COVID-19 were recorded as having died of any cause, and 16/1935 women required ECMO. A large US study published in January 2021 compared outcomes for pregnant women with and without COVID-19 from April–November 2020, drawing the information retrospectively from a database that covers about 20% of the American population. Data was available for 406 446 women hospitalised for childbirth, 6380 (1.6%) of whom had COVID-19. In-hospital maternal death was rare, but rates were significantly higher for women with COVID-19 (141 deaths per 100 000 women, 95% CI 65–268) than for women without COVID-19 (5 deaths per 100 000 women, 95% CI 3.1–7.7).

A preprint (not yet peer reviewed) was released on 9 January 2021 with the results from two large COVID-19 in pregnancy registries. The PAN-COVID registry recorded suspected or confirmed COVID-19 at any stage in pregnancy (in the UK and ten other countries), and the AAP SONPM registry recorded maternal COVID-19 around the time of birth (from 14 days before to 3 days after birth). Maternal mortality was uncommon in both registries: it occurred in 3 of 651 (0.46%) of women with confirmed COVID-19 in the PAN-COVID
registry, and in 5 of 2398 women with COVID-19 (0.21%) in the AAP SONPM registry. For the UK data (PAN-COVID), the mortality rate is likely inflated by under-reporting of women with asymptomatic or mild COVID-19 in pregnancy. The authors of this study have postulated that only 10% of maternal COVID-19 infections were detected as cases, and the true infection fatality rate would therefore be ten times lower (i.e. 0.046%, which is close to the estimate of 0.03% for men and women aged 15–44 years in the UK REACT2 study). Nonetheless, these maternal mortality rates are higher than previously recorded maternal mortality rates in these populations. For example, the maternal deaths from the AAP SONPM registry equate to a perinatal maternal mortality rate of 167 per 100 000 (for women who have COVID-19 around the time of birth), compared with a pre-COVID rate of 17.3 per 100 000 in the USA. Moreover, COVID-19 was listed as the cause of death for all the maternal deaths in these registries where cause of death was known.

The UK Obstetric Surveillance System (UKOSS) published its first report on pregnant women admitted to hospital with confirmed COVID-19 in the UK on 8 June 2020, and an updated report was made available as a preprint on 5 January 2021. This second report covers the period from 1 March 2020 to 31 August 2020. During that time, 1148 hospitalised women had COVID-19 in pregnancy. Most (63%) of women were symptomatic with COVID-19; however, this includes many women from the initial wave of the pandemic, when testing was only performed for symptomatic individuals. As testing for SARS-CoV-2 has become more routinely offered on admission to labour ward, the proportion of asymptomatic women is likely to have increased. Of the 1148 hospitalised pregnant women, 63 (5%) required critical care. During this time, eight women with symptomatic COVID-19 died in hospital. Two of the deaths were not related to COVID-19, and six deaths were, giving a maternal mortality rate of 2.2 hospitalised women per 100 000 maternities (95% CI 0.9–4.3).

Severe illness appears to be more common in later pregnancy. In the UKOSS study, most women were hospitalised in the third trimester or peripartum (bearing in mind that admission at term to give birth will contribute to this distribution). Symptomatic COVID-19 was principally diagnosed in the third trimester: 83% of symptomatic women were diagnosed at or beyond 28 weeks, with 52% diagnosed at or beyond 37 weeks. The reason for hospital admission was known for a subset of pregnant women in the UKOSS study. For asymptomatic women, the reason for admission was principally to give birth (68%). For symptomatic women, the reasons for admission were roughly a third for symptomatic COVID-19, a third to give birth, and a third for other reasons.

The UK Intensive Care National Audit and Research Centre (ICNARC) has released two reports of patients admitted to ICU with COVID-19. The first report covers the start of 2020 up until 31 August 2020. During that time, a total of 70 women who were either currently or recently (within 6 weeks) pregnant had been admitted to intensive care, representing 8.9% of all the 785 pregnant and non-pregnant women admitted aged 16–49 years. The second ICNARC report covers the period from 1 September 2020–early January 2021. During that period, a further 142 women who were either currently or recently (within 6 weeks) pregnant were admitted to intensive care, corresponding to 12% of the 1184 women admitted aged 16–49 years. For context, the conception rate in the UK in 2018 was
75.4 per 1000 women aged 15–44 years, suggesting that the percentage of women pregnant at any one time in the UK is less than 7.5%.²⁷ It is important to note that the threshold for admitting a pregnant woman to ICU is likely to be lower than for a non-pregnant woman: a higher rate of ICU admission for pregnant women does not therefore necessarily mean a higher burden of severe disease.

The MBRRACE-UK consortium published a rapid report on maternal deaths in the UK between March and May 2020.²⁸ During that period, nine women died during pregnancy or in the immediate postpartum period (up to 6 weeks postnatal), and one woman died during the extended postpartum period (up to 1 year). Of these ten women, seven died of COVID-19; in one the cause of death was undetermined but was considered to be probably related to COVID-19, and two died of unrelated causes. It is, at this time, unclear whether the pandemic will result in a statistically significant impact on the overall rate of maternal death in the UK. Key lessons from the report of these deaths have been incorporated into this guidance.

### 1.5.2.2 Data from studies comparing severity of COVID-19 in pregnant and non-pregnant women

It was not clear earlier in the pandemic whether pregnancy itself was a risk factor for severe illness from COVID-19. There is now growing evidence that pregnant women may be at increased risk of severe illness from COVID-19 compared with non-pregnant women, particularly in the third trimester. The most consistent signal of increased severity of COVID-19 in pregnancy is an increase in ICU admissions for pregnant women. However, ICU admission rates must be interpreted with caution, as the threshold for ICU admission for a pregnant woman may be lower than for a non-pregnant woman. Moreover, there is currently no robust data from the UK comparing pregnant and non-pregnant women with COVID-19. The studies in this section are from countries with different healthcare systems, populations and different baseline maternal risks, and should therefore be interpreted with caution from a UK perspective.

Intensive care admission is likely to be more common in pregnant women with COVID-19 than in non-pregnant women with COVID-19 of the same age. The PregCOV-19 Living Systematic Review Consortium analysis¹³ concluded that pregnant women are more likely than non-pregnant women to be admitted to intensive care (OR 1.62, 95% CI 1.33–1.96) and require invasive ventilation (OR 1.88, 95% CI 1.36–2.60). This finding was based overwhelmingly on a single study²⁹ published by the US Centers for Disease Control and Prevention (CDC); in this study two major limitations of the results were acknowledged. The first was that admissions for indications related to pregnancy and those for COVID-19 could not be distinguished. The second was that pregnancy status was missing for three-quarters of the women of reproductive age; a pregnancy rate of 9% was identified – higher than the expected 5%. This could account for significant bias in the results.

Since the last update of that systematic review, a small number of studies from the USA and Mexico have also pointed to increased illness severity from COVID-19 in pregnant women compared to non-pregnant women. The US CDC published an updated study³⁰ in November 2020, based on surveillance of COVID-19 cases in the USA from January–October 2020. This
A study addressed some of the limitations of their earlier work quoted above, although missing data might still have led to bias (e.g. pregnancy status was missing for more than half the cases reported to the CDC). This report compared pregnant women with symptomatic COVID-19 (n = 23,434) to non-pregnant women of reproductive age with symptomatic COVID-19 (n = 386,028). The pregnancy rate in this study was 5.7%, close to the expected value, and by focussing on symptomatic women, this study was less likely to be biased by women being admitted principally for obstetric reasons. This large study found that pregnant women were more likely be admitted to ICU (adjusted risk ratio [aRR] 3.0, 95% CI 2.6–3.4), to receive invasive ventilation (aRR 2.9, 95% CI 2.2–3.8), ECMO (aRR 2.4, 95% CI 1.5–4.0), and to die (1.5 versus 1.2 per 1000 cases; aRR 1.7, 95% CI 1.2–2.4).

A large case–control study from Mexico compared 5183 pregnant women with symptomatic COVID-19 with 5183 matched non-pregnant controls. The data were taken from a prospective cohort of people of any age with clinically suspected SARS-CoV-2 infection who were admitted to one of 475 monitoring hospitals in Mexico. This data therefore suffers from some of the same limitations as the CDC data above, with some outcomes missing for large numbers of individuals. For example, information on ICU admission was only available for one-fifth of pregnant women. Pregnant women had higher odds of death (OR 1.84, 95% CI 1.30–2.61), pneumonia (OR 1.99, 95% CI 1.81–2.19) and ICU admission (OR 2.25, 95% CI 1.86–2.71), but similar odds of intubation (OR 0.93, 95% CI 0.70–1.25).

A smaller study from the New York area also found higher ICU admission rates for pregnant women with COVID-19: 38 pregnant women admitted to hospital with severe or critical COVID-19 were compared to 94 non-pregnant women with severe or critical COVID-19. Pregnant women were only included in this study if they were admitted for treatment of COVID-19 (and not for any obstetric reason). Pregnant women were more likely to be admitted to ICU (39.5% versus 17.0%, P < 0.01; adjusted OR 5.2, 95% CI 1.5–17.5). This was despite the fact that the control group had higher rates of comorbidities (hypertension, diabetes, obesity) and was slightly older. A similar study from France during the initial wave of the pandemic compared the clinical outcomes of 83 pregnant women (above 20 weeks of gestation) with COVID-19 to 107 non-pregnant women with COVID-19, after matching the two groups using a propensity score. Pregnant women were at higher risk for ICU admission than non-pregnant women (11.08% versus 2.38%, P = 0.024), for needing hospital admission because of COVID-19 respiratory decompensation (58.21% versus 17.4%), for the need for oxygen therapy (36.04% versus 17.24%, P = 0.006), and for endotracheal intubation (10.16% versus 1.67%, P = 0.022).

Another study from the US, published in January 2021, compared 22 pregnant women with symptomatic COVID-19 to 240 non-pregnant controls. This study found that pregnant women were more likely than non-pregnant controls to have severe COVID-19, based on two different measures of disease severity (adjusted relative risk [RR] for severe COVID-19 was 3.59 [95% CI 1.49–7.01] for one measure of severity, and 5.65 [95% CI 1.36–17.31] for the other measure of severity). Finally, a study from the Washington State COVID-19 in Pregnancy Collaborative, published at the end of January 2021, found a higher mortality rate for pregnant women with COVID-19 than for non-pregnant controls. This study analysed
data on 240 women who tested positive for COVID-19 in pregnancy. Of these, 24 women (10%) were admitted to hospital specifically for COVID-19-related respiratory concerns; this is approximately three times the hospitalisation rate with COVID-19 compared to all adults aged 20–39 years in Washington state (RR 3.5, 95% CI 2.3–5.3). There were three maternal deaths directly attributed to COVID-19, giving a maternal mortality rate of 1250/100 000 pregnancies (95% CI 257–3653) and a COVID-19 case fatality in pregnancy that was 13.6 times (95% CI 2.7–43.6) higher than for all adults aged 20–39 years. This study also highlighted the increased risk of severe COVID-19 in the third trimester: of the 24 women who were admitted unwell with COVID-19, the median gestation was 32+4 weeks (interquartile range [IQR] 26–36+1 weeks of gestation).

Taken together, these studies point to a possibly increased risk of severe disease from COVID-19 for pregnant women compared to non-pregnant women with COVID-19. However, the most consistent finding was of increased ICU admission rates for pregnant women, and this may in part be explained by a lower threshold for ICU admission in pregnancy in general.

Recent studies on the risk of severe disease from COVID-19 in pregnancy are summarised in Appendix IV, Table 2.

The care of pregnant women with severe COVID-19 is covered in section 5 of this guidance.

1.5.3 Effect on pregnancy

Symptomatic maternal COVID-19 is associated with a two to three times greater risk of preterm birth, principally from iatrogenic preterm birth. The PregCOV-19 Living Systematic Review\(^\text{13}\) estimated the risk of preterm birth at approximately 17%. Most of these preterm births (94%) were iatrogenic. In the initial UKOSS study,\(^\text{23}\) the median gestational age at birth was 38 weeks of gestation (IQR 36–39 weeks of gestation). Of the women who gave birth, 27% had preterm births: 47% of these were iatrogenic for maternal compromise and 15% were iatrogenic for fetal compromise. The updated UKOSS study\(^\text{24}\) confirmed that preterm birth was more likely for women with COVID-19: 19% of women with symptomatic COVID-19 and 9% of women with asymptomatic COVID-19 gave birth before 37 weeks of gestation. Compared to a historical cohort of pregnant women without SARS-CoV-2, pregnant women with symptomatic COVID-19 were more likely to give birth before 32 weeks of gestation (adjusted OR [aOR] 3.98, 95% CI 1.48–10.70) and before 37 weeks of gestation (aOR 1.87, 95% CI 1.23–2.85). Pregnant women with asymptomatic COVID-19 were not, however, at increased risk of preterm birth. For women with symptomatic COVID-19, 78% of preterm births were iatrogenic. Preterm birth is associated with perinatal mortality, but also with long term morbidity.\(^\text{36}\) It is the single biggest cause of neonatal morbidity and mortality in the UK, with about 7% of babies in the UK born preterm.\(^\text{37}\) The preterm birth rate in women with symptomatic COVID-19 appears to be two to three times higher than this background rate. Although the PregCOV-19 Living Systematic Review\(^\text{13}\) found that stillbirth and neonatal death rates were not raised for women with COVID-19, it is concerning that the preterm birth rate is raised to such an extent.
Maternal COVID-19 is also associated with an increased rate of caesarean birth. Again, from the initial UKOSS study, 23% of women had caesarean births; approximately half of these were because of maternal or fetal compromise. The remainder were for obstetric reasons (e.g. progress in labour, previous caesarean birth) or maternal request (6%). Of the women having a caesarean birth, 20% required general anaesthesia (GA). Approximately two-thirds of the women who had a GA were intubated for maternal respiratory compromise, and the other third to facilitate urgent birth. The updated UKOSS data confirmed this trend, with a 49% caesarean birth rate for women with symptomatic COVID-19 versus 29% for a historical control group from 2018 (before COVID-19).

1.6 Risk factors for hospital admission with COVID-19 infection in pregnancy

Risk factors that appear to be associated both with being infected and being admitted to hospital with COVID-19 include:

1. Black, Asian and minority ethnic (BAME) background
2. Having a BMI of 25 kg/m² or more
3. Pre-pregnancy co-morbidity, such as pre-existing diabetes and chronic hypertension
4. Maternal age 35 years or older
5. Living in areas or households of increased socioeconomic deprivation (data not specific to pregnancy).

In addition to these, the risk of becoming infected with SARS-CoV-2 is higher in individuals who are more exposed, for example, those working in healthcare or other public-facing occupations.

In the PregCOV-19 Living Systematic Review,13 the estimates of association were: for age 35 years and older, OR 1.78 (95% CI 1.25–2.55); for BMI 30 kg/m² and above, OR 2.38 (95% CI 1.67–3.39); for chronic hypertension, OR 2.0 (95% CI 1.14–3.48); and for pre-existing diabetes, OR 2.51 (95% CI 1.31–4.80).

The updated report from UKOSS on 1148 pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in the UK between 1 March and 31 August 2020, found that women hospitalised with symptomatic SARS-CoV-2 were more likely to be from a Black, Asian or other minority ethnic background (aOR 6.24, 95% CI 3.93–9.90, aOR 4.36, 95% CI 3.19–5.95 and aOR 12.95, 95% CI 4.93–34.01 respectively), to be overweight or obese (aOR 1.86, 95% CI 1.39–2.48 and aOR 2.07, 95% CI 1.53–2.29 respectively) and to have a relevant medical comorbidity (aOR 1.83, 95% CI 1.32–2.54).
The association between being of BAME background and severe COVID-19 in pregnancy echoes findings from before the pandemic that showed women of BAME background had higher morbidity and mortality in pregnancy than white women. For example, the most recent MBRRACE-UK report of the Confidential Enquiry into Maternal Death and Morbidity 2016–2018 showed that there remains a more than four-fold difference in mortality rates among women from Black ethnic backgrounds and an almost two-fold difference among women from Asian backgrounds compared to white women.

The association between BAME background and severe COVID-19 or death from COVID-19 is not confined to pregnant women. In the UK, 13% of the total population identify as being from a BAME background, but 30% of all individuals admitted to UK critical care for COVID-19 were from BAME backgrounds, and individuals from BAME backgrounds were more likely to die from COVID-19. In the case of COVID-19, it has been postulated that this association may be related to health inequalities or socioeconomic factors; however, further research is needed.

Another possible contributing factor to the observed association between severe illness and BAME background is vitamin D deficiency. UK advice recommends vitamin D supplementation to all pregnant women and individuals of BAME background, regardless of the COVID-19 pandemic.

1.7 Effect of COVID-19 on the fetus

**Key findings**

- Symptomatic maternal COVID-19 is associated with an increased likelihood of iatrogenic preterm birth.
- Aside from preterm birth, there is no evidence that COVID-19 infection has an adverse effect on the fetus or on neonatal outcomes.

Despite over 100 million confirmed COVID-19 infections worldwide, there has been no reported increase in the incidence of congenital anomalies. In the PregCOV-19 Living Systematic Review, there was no evidence of an increase in stillbirth or neonatal death among women with COVID-19, although there was insufficient available evidence to comment on the risk of miscarriage.

There has also been no evidence to date that fetal growth restriction (FGR) is a consequence of COVID-19. The results of two large COVID-19 in pregnancy registries found that the number of small-for-gestational age neonates was comparable to historical and contemporaneous UK and US data; however, growth restriction is considered a theoretical possibility in pregnancies complicated by COVID-19 as two-thirds of pregnancies with SARS were affected by FGR.
For babies born to women with COVID-19, the overall outcomes are positive, with over 95% of newborns included in the PregCOV-19 Living Systematic Review\textsuperscript{13} reported as being born in good condition. A large study\textsuperscript{6} from New York also reported reassuring neonatal outcomes during the pandemic. Of 1481 births overall, 116 (8%) women (giving birth to 120 neonates) tested positive for SARS-CoV-2. All 120 neonates were tested at 24 hours of life and none were positive for SARS-CoV-2. Of 79 neonates who had a repeat SARS-CoV-2 polymerase chain reaction test at age 5–7 days (66% follow-up rate), all tested negative; 72 neonates were also tested at 14 days old and again, none were positive. None of the neonates had signs of COVID-19.

In the updated UKOSS study\textsuperscript{24} 19% of babies born in the UK to women with symptomatic SARS-CoV-2 infection, were admitted to the neonatal unit. These admissions may, in part, represent the policy of the maternity unit rather than concerns about wellbeing of the neonate.

As discussed in section 1.5.3, symptomatic maternal COVID-19 is associated with an increased risk of preterm birth, principally from iatrogenic preterm birth. Preterm birth is a major cause of perinatal mortality, short- and long-term morbidity. The PregCOV-19 Living Systematic Review\textsuperscript{13} estimated the risk of preterm birth at approximately 17%. Most of these preterm births (94%) were iatrogenic and undertaken to improve maternal oxygenation. The updated UKOSS study\textsuperscript{24} confirmed that preterm birth was more likely for women with symptomatic COVID-19: 19% of women with symptomatic COVID-19, and 9% of women with asymptomatic COVID-19 gave birth before 37 weeks of gestation. Compared to a historical cohort of pregnant women without SARS-CoV-2, pregnant women with symptomatic COVID-19 were more likely to give birth before 32 weeks of gestation (aOR 3.98, 95% CI 1.48–10.70) and before 37 weeks of gestation (aOR 1.87, 95% CI 1.23–2.85). Pregnant women with asymptomatic COVID-19 were not at increased risk of preterm birth.

The care of women at risk of iatrogenic preterm birth is addressed in section 5.2.

1.8 Effect of service modifications during the COVID-19 pandemic on maternal and perinatal experience and outcomes

During the first wave of the COVID-19 pandemic, changes were made to the provision of maternity services with the aim of reducing nosocomial transmission, the unintended consequences of which have yet to be determined.

In the UK, two survey studies have demonstrated that during April 2020, the majority of units reduced antenatal and postnatal appointments, adopted remote consultation methods, restricted access to midwifery-led birth settings or home birth, and changed methods of screening for FGR and gestational diabetes.\textsuperscript{47,48} These service changes impacted on the experience of women and their families. An online questionnaire survey\textsuperscript{49} of 1451 pregnant or recently pregnant women in the UK found that the majority felt there were barriers to accessing maternity care while anxieties were expressed about changes to antenatal, intrapartum and postnatal services.
A small, single-centre study\textsuperscript{50} from a London hospital showed an increase in the stillbirth rate during the pandemic (n = 16, 9.31 per 1000 births) compared with pre-pandemic (n = 4, 2.38 per 1000 births; $P = 0.01$). This finding has not been replicated in larger studies. A retrospective review\textsuperscript{51} of maternity statistics to July 2020, from a large maternity unit in Dublin, found no negative impact of service modifications during the pandemic on maternal or neonatal outcomes including stillbirth. The Office for National Statistics\textsuperscript{52} has reported a non-significant decrease in the stillbirth rate in England and Wales from 4.0 stillbirths per 1000 in 2019 to 3.9 in January–September 2020. This has been in line with the long-term trend of decreasing rates of stillbirth.

Meta-analyses and systematic reviews\textsuperscript{53,54} have found higher rates of perinatal mental health disorders during the pandemic, including anxiety and depression. Some of these impacts may be attributed to modifications to maternity services. The MBRRACE-UK rapid report\textsuperscript{28} highlighted two instances where women died by suicide, where referrals to perinatal mental health teams were refused or delayed because of restrictions related to COVID-19.
2. Antenatal care during the COVID-19 pandemic
2. Antenatal care during the COVID-19 pandemic

2.1 What are the considerations for organisation of antenatal care?

Advice

• Women should be advised to continue their routine antenatal care, although it may be modified, unless they meet self-isolation criteria for individuals or households (including social bubbles) with suspected or confirmed COVID-19.

• Service modifications are required to enable social distancing measures, to reduce the risk of transmission between women, staff and other clinic/hospital visitors, and to provide care to women who are self-isolating for suspected or confirmed COVID-19 for whom a hospital attendance is essential.

• The NICE recommended schedule of antenatal care should be offered in full wherever possible. Ideally and where safe, these appointments should be offered in-person, particularly to those from BAME communities, those with communication difficulties or those living with medical, social or psychological conditions that put them at higher risk of complications, or adverse outcomes, during pregnancy.

• Maternity staff should be aware that for some women with hearing or communication difficulties, mask wearing may prevent lip reading.

• Basic assessments such as blood pressure and urine testing, and assessment of fundal height in women not receiving serial fetal growth ultrasound scans, are still required. Trusts and health boards should plan local strategies to ensure women are able to receive this monitoring, even where antenatal care is provided virtually.

  o If it is considered more appropriate for appointments to be conducted remotely, for example during periods of ‘local lockdown’, units should employ teleconferencing or videoconferencing consultations. The limitations of remote consultation methods should be recognised, including being aware that some women will not have sufficient internet access on their mobile devices or other computer hardware.

  o It should be acknowledged that remote appointments, particularly by telephone, may cause new challenges in relationship-building between women and healthcare professionals, especially among socially vulnerable groups, women for whom English is not their first language or women who are hearing impaired.

  o Healthcare professionals should be aware that the women may have unvoiced concerns regarding their care if they have less contact in person.
Healthcare professionals should be aware that women may not have the privacy within their home to disclose private, personal and sensitive information. Efforts should be made at in-person appointments, such as ultrasound scans, to discuss sensitive issues such as domestic violence, sexual and psychological abuse, psychiatric illness and recreational drug use.

- When in-person appointments are required (e.g. for blood tests, maternal examination or ultrasound scans) these should be arranged alongside other in-person maternity appointments to limit repeated clinic attendance.

- Appropriate screening for diabetes in pregnancy should still be provided, following NICE guidance as far as possible, with awareness that modifications to screening protocols are associated with a reduction in the detection of cases of gestational diabetes.

- Particular consideration should be given to pregnant women who have comorbidities which make them clinically vulnerable to the effects of COVID-19. Shared waiting areas should be avoided.
  - If women who are in this group attend hospital, where possible, they should be cared for in single rooms.

- Women should be able to notify the unit regarding non-attendance owing to self-isolation for COVID-19 using standard telephone numbers that are already available to them.
  - There should be a system in place to effectively identify, support and follow up women who have missed appointments.
  - Units should appoint a named midwife or consultant to coordinate care for women unable to attend appointments owing to self-isolation or a positive test. Missed appointments should be reviewed and either rescheduled if an in-person review is necessary or converted to a virtual appointment.

- For women receiving antenatal care across different sites, units must ensure that there are clear pathways for communication via handheld notes, electronic records and correspondence to general practitioners.

- Open access to day assessment and maternity triage services should be maintained. Women should be actively encouraged to attend if they have concerns about their or their baby’s wellbeing.

- Continuity of care should be maintained wherever possible, particularly for women from vulnerable groups who may also be at greater risk from COVID-19.
• Healthcare providers should be aware of specific changes to services which have been suggested through regularly updated subspecialty service guidance available via the RCOG website.

Summary of evidence and rationale for guidance

Antenatal and postnatal care should be regarded as essential and women encouraged to attend, while observing social distancing and infection prevention measures, as recommended by the UK Government. Studies in the UK and internationally have shown that women who do not attend antenatal services are at increased risk of maternal death, stillbirth and other adverse perinatal outcomes. NICE guidance on antenatal care, including the schedule of antenatal appointments recommended for women with uncomplicated pregnancies, is well-established in the UK.

The UK Government has published a list of conditions that make an individual extremely vulnerable to the severe effects of COVID-19, along with guidance on how best to protect these individuals.

A small study in Massachusetts, USA, conducted in spring 2020 (early in the pandemic) showed that there was no relationship between the number of in-person antenatal visits and the risk of developing COVID-19 for pregnant women, suggesting that nosocomial transmission could be minimised. No similar evidence exists for the UK.

Another small survey study from the USA found that the offer of remote appointments to pregnant women at high risk of obstetric complications reduced the rate at which women ‘did not attend’ their appointments, and that 86.9% of women were satisfied with the care received. As discussed earlier, the majority of pregnant or recently pregnant women who participated in an online questionnaire survey felt there were barriers to accessing maternity care while anxieties were expressed about changes to antenatal services including remote consultations.

NHS England has issued guidance on the adoption of remote consultations in secondary care in order to minimise hospital visits. Data directly comparing telephone/video appointments with in-person appointments are not available; until these are, healthcare providers should follow locally agreed guidelines for antenatal care provision.

During the pandemic, modifications to the NICE recommendation to screen for gestational diabetes were suggested to reduce the risk of pregnant women being infected with SARS-CoV-2 during hospital visits. While the number of cases of COVID-19 avoided using this strategy is unknown, evidence has quantified the reduction in diagnoses of gestational diabetes. The rationale for the modified testing strategy is described in the Appendix of the RCOG document Guidance for maternal medicine services in the coronavirus (COVID-19) pandemic.

The use of personal protective equipment (PPE) and facemasks in particular can lead
to difficulties in communication, especially for women with hearing loss. Masks block lip movements and facial expressions and muffle the high frequency portions of sound. Various strategies to improve communication with women of the deaf community have been suggested.67

The care of pregnant women with complex healthcare needs is challenging during a pandemic. To support healthcare providers caring for these women, the following guidance documents to assist maternity units with changes to antenatal and postnatal care were developed and can be found on the RCOG and RCM websites.

• Guidance for antenatal and postnatal services in the evolving coronavirus (COVID-19) pandemic
• Guidance for antenatal screening and ultrasound in pregnancy during the coronavirus (COVID-19) pandemic
• Guidance for maternal medicine in the coronavirus (COVID-19) pandemic (Version 2.5)
• RCM professional clinical briefings:
  o RCM Professional briefing on providing safe and effective virtual consultations
  o RCM Professional briefing on domestic abuse during the pandemic
  o RCM Professional briefing on public health care during the pandemic, including smoking cessation support
  o RCM Professional briefing on antenatal care for women with and without COVID-19

2.2 What are the considerations for antenatal appointments and advice for pregnant women?

Advice

• Staff members should ensure that adequate PPE is used for in-person visits.

• Information and guidance should be available in languages spoken in the local communities served by the maternity unit.

• All women and any accompanying visitors (where permitted) should be advised to wear facemasks or face coverings in line with guidance from national authorities unless exempt.
• Evidence suggests that individuals of BAME background, including pregnant women from these groups, are at higher risk of developing severe complications of COVID-19. Therefore, it is advised that:

  ○ Healthcare providers should discuss these risks with women of BAME background in a sensitive manner.

  ○ Women of BAME background are encouraged to seek advice without delay if they are concerned about their health.

  ○ Healthcare providers should be aware of this increased risk, and have a lower threshold to review, admit and consider multidisciplinary escalation of symptoms in women of BAME background.

  ○ When reorganising services, maternity units should be particularly cognisant of evidence that individuals from a BAME background are at particular risk of developing severe and life-threatening COVID-19 disease.

• Healthcare professionals should proactively advise all pregnant women to contact emergency antenatal services if they have any concern about their or their baby’s wellbeing.

• Carbon monoxide (CO) testing of all pregnant women should be undertaken, where it is safe to do so.

• Women should continue to take folic acid and vitamin D supplements in line with national recommendations.

• Women should be advised that influenza vaccination is still safe at all gestations of pregnancy and is recommended to protect both the woman and baby from the adverse effects of becoming seriously ill with flu during pregnancy.

• Pregnant women will continue to need at least as much support, advice, care and guidance in relation to pregnancy, childbirth and early parenthood as before the pandemic, especially socially vulnerable women (with risk factors including poverty, homelessness, substance misuse, being an asylum seeker, experiencing domestic abuse and mental health problems).

  ○ Midwifery, obstetric and support staff should remain aware of the support needs for all women, acknowledging local and national restrictions on visitors and accompanying persons may affect the amount of support that women require.

• Healthcare providers should be aware of the increased risk of domestic abuse in
pregnancy, which has escalated during the pandemic. Women should be encouraged to share any concerns at every opportunity and be provided with advice and support on how to access the appropriate services if required.

• Healthcare providers should maintain in-person appointments with women when there are safeguarding concerns, in order to provide extra support.

• Women should be asked about their mental health at every contact. Women who require further support should be signposted to resources and local services, which may be provided by virtual means. These include:
  
  o **Sources of self-help for anxiety and stress.**
  
  o Self-referral to local IAPT (Improving Access to Psychological Therapies) services in England. In Scotland, advice is available from Parentclub and NHS Inform. Further information is available from the RCM and Royal College of Psychiatrists websites.

• Women who express concern about their mental health or ‘red flag’ symptoms, such as suicidal thoughts or sudden mood changes, or where their families express these concerns on their behalf, should be supported to access urgent care either through appropriate signposting or, when required in severe cases, by immediate referral.

• Services should establish triage processes to ensure that women with mental health concerns can be appropriately assessed.

**Summary of evidence and rationale for guidance**

The appropriate use of PPE is to protect healthcare workers, women and their families by functioning as a physical barrier to the transmission of infectious particles present in bodily fluids. Units should follow the regularly updated public health guidance issued jointly by the DHSC, Public Health Wales, Public Health Agency (PHA) Northern Ireland, Health Protection Scotland/National Services Scotland, PHE and NHS England (published by PHE on their behalf), and review this in collaboration with their local guidance and infection control teams. There are also clear guidelines on PPE from the RCM.

The UK Government has issued guidelines on the use of face coverings within enclosed spaces in England; these are applicable to women attending outpatient maternity appointments (including scans) and to hospital visitors. Scotland, Northern Ireland and Wales have issued similar guidance.

Before this pandemic, there was already extensive evidence of the inequality of experience and outcomes for women of a BAME background giving birth in the UK. The increased risks of COVID-19 among individuals of a BAME background are likely to result from a number of factors such as socioeconomic disadvantage, and the fact that they are more likely to work in key worker roles, including health and social care. Women of a BAME background...
who are living with socioeconomic deprivation and/or in crowded conditions, those who were born outside the UK and whose first language is not English, and those with a high BMI and/or underlying medical conditions appear to be at particularly high risk.

The RCOG Race Equality Taskforce has launched a joint campaign with FiveXMore that aims to help communication with BAME women, with five easy to remember steps.

There is currently an absence of accurate information about the additional risk of smoking and severe COVID-19 infection. A scientific brief from the WHO on smoking and COVID-19, concludes that smoking is associated with increased severity of disease and death in hospitalised COVID-19 patients. The UK National Centre for Smoking Cessation and Training have advised maternity units to resume carbon monoxide testing on all pregnant women, where it is safe to do so. A risk assessment must be undertaken prior to CO testing including a well ventilated room and being able to maintain a 2 m distance between the woman and healthcare professionals. Recommendations on smoking screening and cessation support are based on previous evidence on the effectiveness of these interventions.

Pregnancy is a risk factor for hospital admission with influenza. Influenza vaccination is safe and effective for pregnant women, who are always included in the annual NHS flu campaign. It is possible to be co-infected with influenza and SARS-CoV-2. The impact of co-infection is not known. In addition, influenza symptoms are difficult to distinguish from COVID-19 symptoms.

Isolation, bereavement, financial difficulties, insecurity and inability to access support systems are all widely recognised risk factors for mental ill health and are expected to affect individuals more than usual during the pandemic. Access to mental health services has also been constrained and delays to accessing care were evident in two maternal deaths by suicide that occurred during the spring of 2020.

This pandemic has resulted in an increased level of anxiety and other mental health problems in the general population. This has had a larger impact on women than on men. There is increasing evidence that this is likely to be even greater for pregnant women, as pregnancy represents a period of additional uncertainty. Specific anxieties are likely to revolve around: a) COVID-19 itself, b) the impact of social isolation resulting in reduced support from wider family and friends, c) the potential of reduced household finances and d) major changes in antenatal and other NHS care, including some appointments being changed from in person to telephone contact. Meta-analyses and systematic reviews have found higher rates of perinatal mental health disorders during the pandemic, including anxiety and depression.

The Royal College of Psychiatrists, in collaboration with NHS England and NHS Improvement, have developed recommendations on mental wellbeing during the COVID-19 pandemic.

The coronavirus pandemic has increased the incidence of domestic abuse. Additional
advice regarding support for victims of domestic abuse during the pandemic is available from the UK government. In addition, Women’s Aid, Save Lives and Refuge have updated guidance for people experiencing domestic abuse during the COVID-19 outbreak.

2.3 How should women with suspected or confirmed COVID-19 needing hospital attendance or advice be cared for?

Advice

For women who telephone maternity services:

- If women report symptoms attributed to COVID-19 on the phone to maternity services, consider differential diagnoses for fever, cough, or shortness of breath. This includes, but is not limited to urinary tract infection, chorioamnionitis and pulmonary embolism.

- If women have symptoms suggestive of COVID-19, they should be advised to self-refer to national services for SARS-CoV-2 testing.

- Maternity units should develop triage tools to assess the severity of illness for women who telephone with suspected or confirmed COVID-19. This should include an assessment of symptoms, clinical and social risk factors and escalation pathways. This should include ‘safety netting advice’ about the risks of deterioration and when to seek urgent medical attention.

For women with possible or confirmed COVID-19, for whom hospital attendance is required or who self-present (this includes women who live with an individual who has possible or confirmed COVID-19):

- These women should be advised to attend via private transport where possible.

- If an ambulance is required, the call handler should be alerted if the woman, or a member of her household, is symptomatic of COVID-19.

- Women should be advised to alert a member of maternity staff by mobile telephone on arrival at the hospital entrance prior to entering any of the buildings.

- Women should be met at the maternity unit or hospital entrance by staff wearing appropriate PPE to provide the woman with a fluid-resistant surgical mask.

- Staff providing care should wear appropriate PPE as per UK health protection guidance.

- Women should be cared for within isolation rooms from which all non-essential items have been removed prior to the woman’s arrival (this includes other rooms in which the woman spends time during her hospital attendance [e.g. scan rooms when bedside scans are not appropriate]).
• Women should immediately be escorted to an isolation room or cohort bay/ward, suitable for the majority of care during their hospital visit or stay.
  o Isolation rooms or ward bays should ideally have a defined area for staff to put on and remove PPE, and suitable bathroom facilities.
• The woman’s facemask should not be removed until she is isolated in a suitable room or cohort bay.
• Only essential staff should enter the isolation room or bay.
• Visitors to isolation rooms or cohort bays/ward should be kept to a minimum and follow local hospital visitor policies.
• All clinical areas must be cleaned following use, according to specific COVID-19 UK-wide public health guidance.

Summary of evidence and rationale for guidance

Maternity units should develop triage tools to assess the severity of illness for women who telephone with suspected or confirmed COVID-19. An example developed by clinicians in Guy’s and St Thomas’ NHS Foundation Trust is provided in Appendix V. Triage tools should include an assessment of symptoms, clinical and social risk factors and escalation pathways. This should include ‘safety netting advice’ about the risks of deterioration and when to seek urgent medical attention.

Availability of resources, provision of services, building/unit configuration and local prevalence of COVID-19 will vary across geographical regions, and will determine how women requiring hospital admission with confirmed or suspected COVID-19 are cared for. Advice on care in isolation rooms and COVID-19 cohort bays is available from PHE, having been issued on behalf of the four nations of the UK. This advice may change frequently and it is vital that healthcare providers stay abreast of the latest developments.

As above, units should follow the regularly updated advice on PPE, in conjunction with guidance from the RCM and their local guidance and infection control teams.

Guidance on cleaning clinical areas used to provide care to women with suspected or confirmed COVID-19 is available from PHE.
2.4 What are the considerations for antenatal care for women who have recovered from COVID-19?

Advice

- For women who have recovered from COVID-19 with mild, moderate or no symptoms, without requiring admission to hospital, antenatal care should remain unchanged following a period of self-isolation.

- Services should ensure that women who have missed antenatal appointments because of self-isolation are seen as early as is practical after the period of self-isolation ends.

- For women who have recovered from a period of serious or critical illness with COVID-19 requiring admission to hospital for supportive therapy, ongoing antenatal care should be planned together with a consultant obstetrician prior to hospital discharge.

- Women who have been seriously or critically unwell from COVID-19 should be offered an ultrasound scan to assess the fetal biometry approximately 14 days following recovery from their illness, unless there is a pre-existing clinical reason for an earlier scan.

Summary of evidence and rationale for guidance

To date, there is an absence of evidence to guide the care for women recovering from mild or moderate symptoms of COVID-19. Women who have recovered should be encouraged to attend antenatal appointments in line with advice statements outlined above.

Placental histopathology studies have found that abnormalities, including fetal vascular malperfusion and villitis of unknown aetiology, are more frequent among COVID-19 cases than controls. Despite these findings, there has been no evidence to date that FGR is a consequence of COVID-19. In contrast two-thirds of pregnancies with SARS were affected by FGR, and until further data becomes available, ultrasound follow-up of women who have been seriously or critically unwell from COVID-19 seems prudent and has been adopted internationally.

Guidance on fetal growth surveillance following COVID-19 was developed along with NHS England and NHS Improvement. This recommends a single fetal growth ultrasound scan a minimum of 14 days following resolution of acute COVID-19 illness which required hospitalisation.
3. Venous thromboembolism prevention
3. Venous thromboembolism prevention

3.1 How should venous thromboembolism be prevented during the COVID-19 pandemic?

Advice

- Women who are self-isolating at home should stay hydrated and mobile.

- Women should have a venous thromboembolism (VTE) risk assessment performed during their pregnancy in line with RCOG Green-top Guideline No. 37a. Infection with SARS-CoV-2 should be considered a transient risk factor and trigger reassessment.

- Where normally indicated, thromboprophylaxis should still be offered and administered as prescribed during the COVID-19 pandemic.

- If healthcare professionals are concerned about the risk of VTE during a period of self-isolation, a clinical VTE risk assessment (in person or by virtual means) should be performed, and thromboprophylaxis considered and prescribed on an individual basis.

- Local procedures should be followed to ensure women are supplied with low molecular weight heparin (LMWH), particularly where they cannot attend hospital during periods of self-isolation.

- Thromboprophylaxis that has been commenced for pregnant women who are self-isolating should be continued until they have recovered from the acute illness (between 7 and 14 days). Advice should be sought from a clinician with expertise in VTE for women with ongoing morbidity and limited mobility.

- All pregnant women admitted with confirmed or suspected COVID-19 should be offered prophylactic LMWH, unless birth is expected within 12 hours or there is significant risk of haemorrhage.

- For women with severe complications of COVID-19, the appropriate dosing regimen of LMWH should be discussed with a multidisciplinary team (MDT), including a senior obstetrician or clinician with expertise in managing VTE in pregnancy.

- All pregnant women who have been hospitalised and have had confirmed COVID-19 should be offered thromboprophylaxis for 10 days following hospital discharge. A longer duration of thromboprophylaxis should be considered for women with persistent morbidity.
If women are admitted with confirmed or suspected COVID-19 within 6 weeks postpartum, they should be offered thromboprophylaxis for the duration of their admission and for at least 10 days after discharge. Consideration should be given to extending this until 6 weeks postpartum for women with significant ongoing morbidity.

Summary of evidence and rationale for guidance

Pregnancy is widely recognised as a hypercoagulable state. The existing RCOG Green-top Guidelines No. 37a and 37b on VTE prevention and management should continue to support decision making during the COVID-19 pandemic. VTE risk assessment in the context of the COVID-19 pandemic should consider both the hypercoagulable state associated with the infection, as well as the increased risk that may come from self-isolation.

Evidence indicates that individuals admitted to hospital with moderate and severe COVID-19 are also hypercoagulable. Infection with SARS-CoV-2 is likely to be associated with an increased risk of maternal VTE. This is likely to be multifactorial, including the reduced mobility resulting from self-isolation at home or hospital admission, and other associated obstetric or maternal morbidity. Consequently, the cumulative risk is difficult to quantify. In the MBRRACE rapid report, one women died from a confirmed thromboembolic event and a second woman experienced a sudden deterioration that may be attributed to a thromboembolic event.

Pregnant women and women who have recently given birth who have tested positive for SARS-CoV-2 will have to self-isolate at home even if they are asymptomatic – this may impact on their mobility which will alter further their VTE risk assessment.

The statements above were developed following expert consensus discussion to determine what increased risk COVID-19 may pose to pregnant women. VTE prevention for the unwell woman with COVID-19 is considered in section 5.2.
4. Labour and birth during the COVID-19 pandemic
4. Labour and birth during the COVID-19 pandemic

Women admitted to hospital, including maternity units, should be offered testing for SARS-CoV-2 on admission. This includes women admitted for intrapartum care.

4.1 What are the considerations for labour and birth in asymptomatic women who test or have tested positive for SARS-CoV-2?

Advice

- Low risk women who test positive for SARS-CoV-2 within 10 days prior to birth who are asymptomatic and wish to give birth at home or in a midwifery-led unit, should have an informed discussion around place of birth with their clinician.

- For asymptomatic women who test positive for SARS-CoV-2 on admission, continuous electronic fetal monitoring (CEFM) during labour using cardiotocography (CTG) is not recommended solely due to a positive test.
  - Fetal monitoring options should be discussed with the woman, acknowledging the current uncertainties in women who are asymptomatic with a positive test for SARS-CoV-2.
  - Women who test positive for SARS-CoV-2 should be offered delayed cord clamping and skin-to-skin contact with their baby in line with usual practice.

Summary of evidence and rationale for guidance

NHS England and NHS Scotland have recommended that women (and their support partners in NHS England) should be offered testing for SARS-CoV-2 when they are admitted to maternity units to give birth.

While fetal compromise in women who are symptomatic of COVID-19 has been reported by some case series,\textsuperscript{97,98} it is reassuring that measures of fetal compromise at birth for asymptomatic women who test positive for SARS-CoV-2 are not reported to differ from women who test negative.\textsuperscript{99}

The need for CEFM for asymptomatic women who test positive for SARS-CoV-2 but who are otherwise low risk for labour (e.g. CEFM would not otherwise be indicated by NICE Clinical Guideline [CG190] on Intrapartum care for healthy women and babies\textsuperscript{100}) is an area of clinical uncertainty because of the lack of robust evidence. It is, therefore, important that asymptomatic women of low obstetric risk should continue to have the risks and benefits of CEFM discussed with them on a holistic basis.

There is no evidence\textsuperscript{79} that the practice of delayed cord clamping and skin-to-skin contact between mother and baby increases the transmission of SARS-CoV-2 to the neonate. The
well documented benefits of these practices should be discussed with the woman to make an informed choice and implemented in line with pre-pandemic practice. In the absence of other evidence, NICE CG190 should be followed.100

4.2 How should a woman with suspected or confirmed COVID-19 be cared for in labour if they are symptomatic?

Advice

• Women with mild COVID-19 symptoms can be encouraged to remain at home (self-isolating) in early (latent phase) labour consistent with routine care.

• If there are no concerns regarding the health of either the woman or baby, women who attend the maternity unit and would usually be advised to return home until labour is more established can still be advised to do so, unless private transport is not available.
  o Women should be provided with the usual advice regarding signs and symptoms of labour; but also be informed about symptoms that might suggest deterioration related to COVID-19 and be advised to call back if concerned.

• Advice on PPE is available in section 4.8.

• Women with symptomatic suspected or confirmed COVID-19 should be advised to labour and give birth in an obstetric unit.

• On admission, a full maternal and fetal assessment should be undertaken, including:
  o Assessment of the severity of COVID-19 symptoms by the most senior available clinician.
  o Maternal observations including temperature, respiratory rate and oxygen saturation.
  o Confirmation of the onset of labour, as per standard care.
  o CEFM using CTG.

• The following members of the MDT should be informed of the woman’s admission: consultant obstetrician, consultant anaesthetist, midwife-in-charge, consultant neonatologist, neonatal nurse-in-charge and the infection control team. Other members of the team may include an obstetric physician or respiratory physician.

• Standard hourly maternal observations and assessment should be performed (as per the recommendations in NICE CG190, Intrapartum care for healthy women and
babies), with the addition of hourly oxygen saturation monitoring. Oxygen therapy should be titrated to aim for saturation above 94%.

- CEFM should be offered to women with symptomatic suspected or confirmed COVID-19 during labour and vaginal birth.
- Maternal infection with SARS-CoV-2 is in itself not a contraindication to performing a fetal blood sample or using fetal scalp electrodes.
- The number of staff members entering the room should be minimised, and units should develop a local policy specifying essential personnel for emergency scenarios.
- Women with symptomatic suspected or confirmed COVID-19 should be offered delayed cord clamping and skin-to-skin contact with their baby if the condition of the woman and infant allows.

Summary of evidence and rationale for guidance

NHS England has produced clinical guidance on the temporary reorganisation of intrapartum maternity care during the coronavirus pandemic and a framework has been published in Scotland.

COVID-19 infection and control guidance issued by PHE, on behalf of the four nations of the UK, gives advice about avoiding disease transmission. WHO has produced guidance on clinical management of COVID-19.

In women with symptomatic COVID-19, there may be an increased risk of fetal compromise in active labour. In addition, it is reported that women with symptomatic COVID-19 have an increased risk of caesarean birth, which further supports the guidance to give birth in an obstetric unit where timely access to emergency care is available.

While further data is required in women with symptomatic confirmed or suspected COVID-19, it appears prudent to use CEFM, as would usually be recommended for maternal systemic infection.

There is no evidence that the practice of delayed cord clamping and skin-to-skin contact between woman and baby increases the transmission of SARS-CoV-2 to the neonate.

4.3 What are the considerations for labour and birth for women who have recovered from COVID-19?

Advice

- For women who have recovered from antenatal COVID-19 without requiring admission to hospital, and who have completed self-isolation in line with public...
health guidance, there should be no change to planned care during labour and birth.

- For women who have recovered following a hospital admission for serious or critical COVID-19 illness needing supportive therapy, healthcare professionals should discuss and plan place of birth with the woman. While making a personalised assessment, consideration should be given to both the growth of the fetus and the woman’s choices.

- Healthcare professionals should ensure that any recent growth ultrasound scan undertaken following a period of severe illness has been reviewed. If the interval between resolution of illness and presentation for birth has been insufficient to allow for a growth scan, the implications of this should be considered in the assessment and care plan.

- When participating in informed discussions with women about fetal monitoring, healthcare professionals should acknowledge evidence of fetal distress is based on small numbers of babies born to women symptomatic of COVID-19, and theoretical risks extrapolated from pregnancies affected by FGR in women with other coronaviruses.

Summary of evidence and rationale for guidance

There is an absence of evidence for this situation. The above is based on expert consensus.

4.4 What are the considerations for birth partners during the COVID-19 pandemic?

Advice

- Women should be supported and encouraged to have a birth partner present with them during active labour and birth if they wish to do so.

- Birth partners who are symptomatic, or in a period of self-isolation for confirmed SARS-CoV-2 infection, should remain in self-isolation at home and not attend the hospital.

- NHS England recommends efforts should be made to utilise the available testing capacity to test both the woman and her birth partner to mitigate infection risk where resources allow.

- Local level risk assessments should be made for each maternity service space (for example shared wards) to identify if there are elevated risks of SARS-CoV-2 transmission from the presence of a birth partner.
• On attendance at the maternity unit, all birth partners should be asked whether they have experienced any symptoms suggestive of COVID-19 in the preceding 10 days, e.g. fever, acute persistent cough, changes in or loss of sense of smell (anosmia) or taste.
  
  o If they have had symptoms within the last 10 days, the birth partner should leave the maternity unit immediately and self-isolate at home, unless they have had a negative test result for SARS-CoV-2 since the onset of symptoms.
  
  o If they have had a fever within the last 48 hours, birth partners should leave the maternity unit immediately and self-isolate at home, regardless of their test result.

• Birth partners, not otherwise advised to be self-isolating, should be allowed to stay with the woman through labour and birth, unless the birth occurs under general anaesthetic. Further guidance about access to maternity services for a birth partner and other supportive adults has been published by the NHS and should be followed as far as possible.

• Birth partners should wear a face covering unless exempt, remain by the woman’s bedside, be advised not to walk around the ward/hospital and should wash their hands frequently.

• Restrictions on visitors should follow local hospital policy.

• Trusts and health boards should prioritise the birth partners of women who require continuous support, such as women with disabilities, communication challenges or complex medical, mental health or social factors.

Summary of evidence and rationale for guidance

Having a trusted birth partner present throughout labour is known to make a significant difference to the safety and wellbeing of women in childbirth. The pandemic has affected the levels of perinatal stress experienced by pregnant women, as well as feelings of fear and loneliness in relation to their birth experience. A supportive birth partner is a recognised protective factor for the emotional wellbeing and birth experiences of women.

UK-wide PHE guidance, local hospital infection control and visitor policies should be adhered to.

The NHS has produced guidance to support the access of birth partners and other supportive adults to maternity services in England and Scotland.
4.5 What informed discussions should take place with women regarding timing and mode of birth during the COVID-19 pandemic?

Advice

• Clinicians should discuss mode of birth during the COVID-19 pandemic with the woman and her family. Consideration should be given to her preferences and any obstetric or fetal indications for intervention.

• A personalised assessment should take place to determine whether it is beneficial overall to delay a planned caesarean birth or induction of labour (IOL), and any associated appointments, for women who are self-isolating because of suspected COVID-19 in themselves or in a household contact.
  
  o Consider the urgency of the birth and the risk of infectious transmission to other women, healthcare workers and, postnatally, to her baby.

  o If a planned caesarean birth or IOL cannot be delayed, follow the advice for services providing care to women admitted with suspected or confirmed COVID-19.

• Women with worsening symptoms, or who are becoming exhausted, should be offered personalised information so they can make an informed decision about expediting birth.

• Senior obstetric and medical input should be sought when urgent birth of the baby is required to aid supportive care of a woman with severe or critical COVID-19 and vaginal birth is not imminent. Consider whether the benefits of an urgent caesarean birth outweigh any risks to the woman.

• The advice in section 4.8 on PPE for caesarean birth should be followed.

• Women and their families should be informed that donning PPE for emergency caesarean births is time-consuming but essential, and this may impact on the time it takes to assist in the birth of the baby. Consider this during decision making and, where possible, discuss during birth planning.

Summary of evidence and rationale for guidance

There is no evidence to favour one mode of birth over another in women with COVID-19. In the earlier UKOSS study, one (5%) babies tested positive for SARS-CoV-2 infection; six within the first 12 hours (two were born by unassisted vaginal birth and four by caesarean birth) and six after 12 hours (two born vaginally and four by caesarean birth). The rate of neonatal COVID-19 infection is no greater when babies are born vaginally, breastfed or stay with their mother after birth.
Donning PPE is expected to lengthen the decision to birth interval because of the additional action required before commencing surgery, however, there is no evidence of this within the UK setting. A single centre cohort study demonstrated a possible longer time to birth in urgent caesarean births for women with suspected or confirmed COVID-19 (25.5 minutes [95% CI 17.5–31.75] versus 18.0 minutes [95% CI 10.0–26.25]; \( P = 0.113 \)). This did not reach statistical significance, which may be explained by the study sample size which was not chosen to power for the outcome. Simulation training has been proposed as a way of improving the response to obstetric emergencies during the COVID-19 pandemic, including donning and doffing of PPE.

### 4.6 What are the considerations for water birth?

**Advice**

- Water birth is not contraindicated for women who are asymptomatic of COVID-19 and presumed or confirmed SARS-CoV-2 swab negative, providing adequate PPE can be worn by those providing care.

- Women with symptomatic COVID-19 who have a cough, fever or feel unwell, should not labour and birth in water.

- Asymptomatic women who have tested positive for SARS-CoV-2 should be advised there is inadequate evidence about the risk of transmission of the virus in water.

- Healthcare providers should be aware that the integrity of PPE, such as a facemask, could be compromised when it becomes wet.

**Summary of evidence and rationale for guidance**

Labour and birth in water may confer benefits to women at low risk of complications during birth. Women report that restrictions to access water birth are a concern during the pandemic, and therefore in the absence of contraindication to water birth, this option should be available. Care providers should discuss with women the lack of evidence on this topic in the context of the COVID-19 pandemic in order to facilitate informed decision making.

A lack of evidence about the risks of transmission of the virus in water exists. There is evidence that SARS-CoV-2 RNA may be present in faeces, but no evidence to support that this has resulted in faecal–oral spread. However, there is a small theoretical risk that water contaminated with faeces or other maternal secretions could pose an infection risk to the baby or the staff caring for a woman birthing in water. There is, therefore, insufficient evidence for or against the use of water in labour or birth for asymptomatic women and staff caring for them; this risk also applies when caring for a woman during labour out of water.

The RCOG and RCM have sought advice from the UK Infection Prevention and Control Cell about this issue, who have suggested that women who, within 10 days of birth, test positive for; or have symptoms of, COVID-19 should be advised against birth in water.
It is recommended that women with pyrexia should not labour or birth in water. Women with a cough or breathing difficulties, or those who feel unwell, should be closely monitored for their oxygen saturations and other vital signs and may require oxygen support. This care is better provided out of water to enable more effective monitoring and rapid access to emergency care.

### 4.7 What are the specific considerations for labour analgesia or anaesthesia?

#### Advice

- Entonox (50% nitrous oxide and 50% oxygen) can be safely offered with a standard single-patient microbiological filter.

- The option of epidural analgesia should be discussed with women with suspected or confirmed COVID-19 when they are in early labour so they can make informed decisions regarding use or type of labour analgesia. Women should be informed that the use of epidural analgesia may avoid the need for general anaesthesia (GA) in some cases, and the associated additional risks in this scenario.

#### Summary of evidence and rationale for guidance

Advice published on the considerations for labour analgesia or anaesthesia is based on expert opinion following consultation with the Obstetric Anaesthetists Association (OAA).

There is no evidence that the use of Entonox is an aerosol-generating procedure (AGP).

There is no evidence that epidural or spinal analgesia or anaesthesia is contraindicated in the presence of coronaviruses.

Intubation, required for GA, is an AGP. This significantly increases the risk of transmission of SARS-CoV-2 to attending staff.

UK case studies reported significantly lower rates of GA for caesarean births (down from 7.7% to 3.7%), as well as lower rates of conversion from neuraxial to GA during the initial wave of the SARS-CoV-2 infection in 2020. Recommendations for anaesthetic decision making made by the OAA are thought to have been influential in the decline in GA rate. This supports the guidance that clinicians should facilitate fully informed discussions regarding choice of analgesia early in labour for women with suspected or confirmed COVID-19.

### 4.8 What personal protective equipment is recommended when caring for women during labour and birth?

#### Advice

- Healthcare professionals should follow national recommendations on the use of PPE in clinical settings.
Owing to the differing levels of PPE required for caesarean birth, a multidisciplinary discussion should be held about the likelihood of a woman requiring a GA.

For caesarean births where GA is planned from the outset all staff in theatre should wear PPE, including an FFP3 mask and visor. PPE should be donned prior to commencing the GA.

Local standard operating procedures should be developed to determine the type of PPE required in cases where GA is not planned from the outset, but neuraxial anaesthesia for caesarean birth either cannot be sited or is ineffective.

Summary of evidence and rationale for guidance

The appropriate use of PPE is to protect healthcare workers, women and their families by functioning as a physical barrier to the transmission of infectious particles present in bodily fluids. General advice from PHE, issued on behalf of the four nations of the UK, on type and specification of PPE is available. The RCM and the OAA have provided specific advice on the type and specification of PPE for maternity care and obstetric anaesthesia.

The level of PPE required by healthcare professionals caring for a woman with COVID-19 who is undergoing a caesarean birth should be determined on the basis of the risk of her requiring a GA, which would require intubation and is, therefore, an AGP.

The provision of neuraxial anaesthesia (spinal, epidural or combined spinal epidural [CSE]) is not an AGP.

The chance of requiring conversion to a GA during a caesarean birth commenced under neuraxial anaesthesia is small, but this chance increases with the urgency of caesarean birth. In situations where there are risk factors that make conversion to a GA more likely, the decision on what type of PPE to wear should be based on the individual circumstances. If the risk of requiring conversion to a GA is considered significant (e.g. in a category 1 caesarean birth), the theatre team should wear PPE appropriate to a GA in readiness.

A retrospective analysis of anaesthetic practices for caesarean births in maternity units in the north-west of England during the initial wave of the COVID-19 pandemic, found a reduction in GA rates (7.7% before the pandemic to 3.7% during). Further there was a reduction in conversion rates from neuraxial to GA (1.7% to 0.8%). The key factors identified for these reductions included anaesthetic decision-making, recommendations from anaesthetic guidelines and the increased presence of on-site anaesthetic consultants. This is encouraging but should be interpreted with some caution as the authors did not report neonatal outcomes.
4.9 How should obstetric theatres be managed during the COVID-19 pandemic?

Advice

- Elective obstetric procedures such as caesarean birth or cervical cerclage that are planned for women with suspected or confirmed COVID-19, should ideally be scheduled at the end of the operating list.

- Emergency procedures for women with suspected or confirmed COVID-19 should be conducted in a second obstetric theatre where available, allowing time for a full postoperative theatre clean as per national health protection guidance.

- The number of staff in the operating theatre should be kept to a minimum and all colleagues should wear appropriate PPE.

- Anaesthetic care for women with suspected or confirmed COVID-19 should be provided with reference to guidance from the Royal College of Anaesthetists (RCoA)/OAA.

- Operating theatre checklists should be used to aid closed loop communication as the wearing of PPE compromises communication.

Summary of evidence and rationale for guidance

The advice above is based on UK government advice on infection prevention and control, guidance from the RCoA and OAA, and expert consensus. The use of PPE causes communication difficulties in operating theatre settings, including obstetric theatres. It is proposed that operating theatre checklists should be employed to improve communication in operating theatres.

4.10 What are the considerations for bereavement care during the COVID-19 pandemic?

Advice

- Maternity services should ensure that bereavement care remains of a high standard during the COVID-19 pandemic, with continued provision of appropriate intrapartum and postnatal care, including all appropriate investigations and postnatal appointments.

- Women should be supported and encouraged to have a support person accompany them to all care episodes related to a pregnancy loss if they wish.
Summary of evidence and rationale for guidance

Sands and the RCM have provided further guidance on bereavement care during the pandemic in their briefing *Bereavement Care in Maternity Services During COVID-19 pandemic*. Sands has also produced information for bereaved families about care during the pandemic.
5. Managing clinical deterioration during the COVID-19 pandemic
5. Managing clinical deterioration during the COVID-19 pandemic

5.1 How should a pregnant woman requiring hospital admission with symptoms suggestive of COVID-19 be cared for?

**Advice**

- Women presenting with a fever should be cared for in line with RCOG Green-top Guideline No. 64a *Bacterial Sepsis in Pregnancy*. Testing for SARS-CoV-2 should be offered in addition to blood cultures.

- While pyrexia may suggest COVID-19, clinicians should not assume that all pyrexia is because of COVID-19. The possibility of bacterial infection should be considered and a full sepsis screen performed in line with the [UK Sepsis Trust Sepsis Screening and Action Tool](https://www.uksepsistrust.org.uk/sepsis-screening-action-tool) and intravenous (IV) antibiotics administered when appropriate.

- Bacterial (rather than viral) infection should be considered if the white blood cell count is raised (lymphocytes are usually normal or low with COVID-19) and antibiotics should be commenced.

- Radiographic investigations should be performed as for the non-pregnant adult; this includes chest X-ray and computerised tomography (CT) of the chest.

  - Chest imaging is essential for the evaluation of the unwell woman with COVID-19 and should be performed when indicated, and not delayed because of concerns of possible maternal and fetal exposure to radiation, as maternal wellbeing is paramount.

- A diagnosis of pulmonary embolism or heart failure should be considered for women presenting with chest pain, worsening hypoxia or a respiratory rate above 20 breaths/minute (particularly if there is a sudden increase in oxygen requirements), or in women whose breathlessness persists or worsens after expected recovery from COVID-19.

- Additional tests to investigate for possible differential diagnoses, including electrocardiogram, echocardiogram, CT pulmonary angiogram, ventilation perfusion lung scan, should be considered.

**Summary of evidence and rationale for guidance**

The clinical symptoms of COVID-19 overlap with those of a variety of other clinical conditions. Healthcare providers should consider all differential diagnoses for women who present with a fever in pregnancy and follow the advice and guidance of the RCOG Green-top Guideline No. 64a. 121
Several studies\textsuperscript{122} have shown decreased lymphocyte counts in the general population affected by COVID-19. One systematic review\textsuperscript{123} noted decreased lymphocyte counts in pregnant women.

5.2 How should a pregnant, or recently pregnant woman with suspected or confirmed COVID-19 who is clinically deteriorating be cared for?

**Advice**

**Organisation and principles of care**

- Obstetricians should be familiar with and follow local guidelines for the initial investigation and care of women presenting with possible COVID-19.

- Women with suspected COVID-19 should be treated as though it is confirmed until test results are available.

- The priority for medical care should be to stabilise the woman's condition with standard therapies.

- An urgent MDT meeting should be arranged for any unwell woman with suspected or confirmed COVID-19. This includes women who are requiring oxygen to maintain saturations between 94% and 98%, women with a respiratory rate above 20 breaths/minute and women with a heart rate greater than 110 beats/minute. This should ideally involve senior decision makers and may include: a consultant obstetrician, consultant anaesthetist, midwife-in-charge, consultant neonatologist, neonatal nurse-in-charge, intensivist responsible for obstetric care, an obstetric physician, a respiratory physician and the infection control team. The discussion should be shared with the woman, and her family if she chooses. The following should be considered:
  - Key priorities for medical care of the woman and her baby, and her birth preferences.
  - The most appropriate location of care (e.g. intensive care unit, 'COVID bays', specific COVID-19 wards, isolation room in infectious disease ward or other suitable isolation room) and lead specialty.
  - Concerns among the team regarding special considerations in pregnancy, including the health of the baby.

- A consultant in obstetrics and gynaecology should review all pregnant and recently pregnant women with suspected or confirmed COVID-19 who are in hospital at least daily, even if they are not admitted to the maternity unit.

- If appropriate, a designated team member should be responsible for regularly updating the woman's family about her health, and that of the baby.
Observations and investigations

• Clinicians should monitor both the absolute values and trends of the hourly observations, including heart rate, respiratory rate and oxygen saturation.

• Clinicians should be aware that young, fit women can compensate for deterioration in respiratory function and are able to maintain normal oxygen saturations until sudden decompensation.

• Units should have an escalation plan for the care of pregnant and postnatal women with COVID-19.

• The woman’s care should be escalated urgently if any of the following signs of decompensation develop:
  - increasing oxygen requirements or fraction of inspired oxygen (FiO₂) above 35%,
  - increasing respiratory rate despite oxygen therapy of or above 25 breaths/minutes or a rapidly rising respiratory rate,
  - reduction in urine output when this is being monitored,
  - acute kidney injury (serum creatinine levels above 77 µmol/l in women with no pre-existing renal disease),
  - drowsiness, even if the oxygen saturations are normal.

• The possibility of myocardial injury should be considered, as the symptoms are similar to those of respiratory complications of COVID-19.

• The frequency and suitability of fetal heart rate monitoring should be considered on an individual basis, accounting for the gestational age and the maternal condition.

Interventions

• If there is clinical uncertainty about whether to offer a therapy to a pregnant woman, advice should be sought through maternal medicine networks.

• Oxygen should be titrated to target saturations to 94–98%.

• Caution should be applied to IV fluid management:
  - Hourly fluid input/output charts should be used to monitor fluid balance in women with moderate to severe symptoms of COVID-19.
The aim should be to maintain a neutral fluid balance in labour.

When required, boluses in volumes of 250–500 ml should be employed and an assessment for fluid overload made before proceeding with further fluid resuscitation.

Antibiotics should be commenced at presentation if there is clinical suspicion of bacterial infection or sepsis, with an early review and rationalisation of antibiotics if COVID-19 is confirmed. Even when COVID-19 is confirmed, clinicians should remain open to the possibility of another coexisting condition.

There should be no delay in the administration of therapy that would usually be given in maternity care (e.g. IV antibiotics in woman with fever and prolonged rupture of membranes).

All pregnant women should be assessed for risk of VTE and prescribed thromboprophylaxis with LMWH unless there is a contraindication (see section 3.1). The dose of LMWH should be considered on an individual basis and discussed with the MDT. Therapeutic doses of LMWH should be employed when VTE is suspected until objective testing can be undertaken.

Thrombocytopenia may be associated with severe COVID-19. For women with thrombocytopenia (platelets less than 50 × 10^9/l) aspirin and LMWH thromboprophylaxis should be discontinued and haematology advice sought.

The use of mechanical aids (such as intermittent pneumatic compression) should be used if LMWH therapy is contraindicated or paused secondary to thrombocytopenia.

Corticosteroid therapy should be considered for 10 days or up to discharge, whichever is sooner, for women who are unwell with COVID-19 and requiring oxygen supplementation or ventilatory support. One suggested steroid regimen is:

- If steroids are not indicated for fetal lung maturity, oral prednisolone 40 mg once a day, or IV hydrocortisone 80 mg twice daily, for 10 days or until discharge, whichever is sooner.

- If steroids are indicated for fetal lung maturity, intramuscular dexamethasone 6 mg every 12 hours for four doses, then oral prednisolone 40 mg once a day, or IV hydrocortisone 80 mg twice daily, to complete a total of 10 days or until discharge, whichever is sooner.

Remdesivir should be avoided in pregnant women with COVID-19 unless clinicians believe the benefits of treatment outweigh the risks to the individual. Any decision to treat with remdesivir should be taken by an MDT that includes obstetric and infection specialists. Clinicians should be aware that the fetal risk profile of remdesivir is largely unknown.
• When considering the use of remdesivir in women with COVID-19 who are breastfeeding, clinicians should consider the benefits and risks of treatment, and use only in women where benefit has been reported (hospitalised patients requiring oxygen therapy, especially early in disease course, and not in patients who are mechanically ventilated). Any decision to treat with remdesivir should be taken by an MDT that includes obstetric and infection specialists.

• The interleukin-6 receptor antagonist (anti-IL6) tocilizumab has been shown to improve outcomes, including survival, in hospitalised patients with hypoxia (oxygen saturation below 92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein at or above 75 mg/l). Although data for the use of tocilizumab in pregnancy in this situation are limited, there is currently no compelling evidence that tocilizumab is teratogenic or fetotoxic. For women meeting the criteria above (hypoxic with systemic inflammation), the use of tocilizumab should be considered. It is recommended that any decision to treat with anti-IL6 agents should be taken by an MDT to include obstetric and infection specialists, and given if the benefits outweigh the risks.

• Other therapies are being investigated for the management of COVID-19, and pregnant women should be offered the opportunity to enrol in clinical trials (such as the RECOVERY trial) for which they are eligible. Hydroxychloroquine, lopinavir-ritonavir and azithromycin have been shown to be ineffective in treating COVID-19 infection and should not be used for this purpose.

Planning for the birth of the baby

• For pregnant women in the third trimester who are unwell, an individualised assessment should be undertaken by the MDT to decide whether emergency caesarean birth or IOL should be prioritised, either to facilitate maternal resuscitation (including the need for prone positioning) or because of concerns regarding fetal health.

• If maternal stabilisation is required before delivery can be undertaken safely, this is the priority, as it is in other maternity emergencies.

• If urgent intervention for birth is indicated for fetal reasons, then birth should be expedited as for usual obstetric indications, as long as the maternal condition is stable.

• When iatrogenic preterm birth is required, the administration of antenatal corticosteroids to promote fetal lung maturation and magnesium sulfate for fetal neuroprotection, should be considered by the MDT. Urgent intervention for birth should not be delayed for their administration.
Summary of evidence and rationale for guidance

A useful summary on supportive care for adults diagnosed with COVID-19 has been published by WHO. Specific guidance on the care of patients with COVID-19 who are admitted to critical care has been published by NICE and SIGN.

Hospitals should have escalation guidelines for the care of pregnant and postnatal women with COVID-19. An example of a maternity escalation plan from Guy’s and St Thomas’ NHS Foundation Trust is given in Appendix VI.

As discussed in section 3.1, infection with SARS-CoV-2 requiring admission to hospital is associated with an increased risk of VTE. All pregnant and recently pregnant women should be assessed for risk of VTE and prescribed thromboprophylaxis with LMWH unless there is a contraindication. The dose of LMWH should be considered on an individual basis and discussed with the MDT. There is currently not enough evidence of the benefits and risks of therapeutic dose anticoagulation applicable to pregnant women who may require imminent operative birth, to recommend therapeutic anticoagulation routinely in the absence of suspected or proven VTE.

While most patients with severe COVID-19 infection will have normal or even high platelet counts, it can be associated with thrombocytopenia. When aspirin has been prescribed as prophylaxis for pre-eclampsia, it should be discontinued for the duration of the infection as this may increase the bleeding risk in thrombocytopenic women. Women who take LMWH thromboprophylaxis during pregnancy should discontinue this if their platelet count falls below 50 x 10⁹/l and their care should be discussed with a haematologist.

Myocardial injury and its complications were observed in 11% of all patients who died in Italy up to 4 June 2020. Early involvement of multidisciplinary colleagues to investigate for potential myocardial injury is essential if this is suspected. Further details of investigation and management is available in the NICE rapid guideline on diagnosing myocardial injury in patients with suspected or confirmed COVID-19.

Increased rates of iatrogenic preterm birth are associated with severe COVID-19 infection in pregnancy (sections 1.5.3 and 1.7). Antenatal corticosteroids are well established as being beneficial in preterm labour, or if iatrogenic preterm birth is anticipated. There is no evidence that steroids in the doses prescribed for fetal lung maturation cause any harm in the context of COVID-19, but there is also limited evidence of safety, and the unknown effect on maternal outcome should be weighed against the neonatal benefit particularly at later preterm gestations. Magnesium sulfate therapy is recommended for neuroprotection of the neonate, and should be offered to women up to 29⁴⁶ weeks of gestation and considered up to 33⁴⁶ weeks of gestation. The administration of steroids and magnesium sulfate to women who are severely unwell with COVID-19 should be considered by an MDT.

For non-specialist anaesthetists and physicians involved in the care of pregnant women with COVID-19 and other medical conditions, useful information is available from the RCoA
Prone positioning of patients with moderate to severe acute respiratory distress syndrome (ARDS) can improve respiratory function and has been recommended for the care of patients with COVID-19. There is little evidence on the use of prone positioning in pregnancy and guidance from the Intensive Care Society in the UK advises that it is relatively contraindicated in the second and third trimesters of pregnancy. However, a review article on prone positioning for pregnant women who are unwell with COVID-19 provides advice, guidance and an algorithm on how this can be undertaken successfully in the second and early third trimesters.

The interim results of the RECOVERY trial demonstrated a significant reduction in 28-day mortality for individuals with COVID-19 requiring oxygen who were given corticosteroid therapy (age-adjusted rate ratio 0.83, 95% CI 0.75–0.93; P < 0.001). The RECOVERY trial protocol for pregnancy recommends oral prednisolone 40 mg once daily, and, in women unable to take oral medicine, IV hydrocortisone 80 mg twice daily instead of dexamethasone treatment. Unlike dexamethasone, prednisolone and hydrocortisone are extensively metabolised in the placenta with minimal transfer to the fetus. While the neonatal benefits of antenatal corticosteroids (betamethasone and dexamethasone) are well-established when administered to women at risk of imminent preterm birth (NICE NG25), exposure to repetitive doses of steroids is associated with adverse neonatal outcomes. It is, therefore, recommended that if corticosteroids are not indicated for fetal lung maturity, oral prednisolone 40 mg once a day, or IV hydrocortisone 80 mg twice daily, should be administered for 10 days or up to discharge, whichever is sooner. If steroids are indicated for fetal lung maturity, intramuscular dexamethasone 6 mg every 12 hours for four doses, then oral prednisolone 40 mg once a day, or IV hydrocortisone 80 mg twice daily, should be given for 10 days or up to discharge, whichever is sooner.

The interim results of the WHO Solidarity trial have reported that the antiviral agent remdesivir had little or no effect on overall mortality, initiation of ventilation and duration of hospital stay, in hospitalised patients with COVID-19. Other antiviral drugs examined in this trial including hydroxychloroquine, lopinavir and interferon beta-1a, showed similar results to remdesivir. Since the safety of remdesivir in pregnancy is largely unknown, it is recommended that it should be avoided in pregnant women with COVID-19 unless clinicians believe the benefits of treatment outweigh the risks to the individual. In breastfeeding women with COVID-19, the use of remdesivir should be restricted to women where benefit has been reported (hospitalised patients requiring oxygen therapy, especially early in disease course, and not in patients who are mechanically ventilated). Any decision to treat with remdesivir should be taken by an MDT and, when feasible, in discussion with the woman.

Anti-IL6 agents, tocilizumab and sarilumab, have been investigated on adult patients with COVID-19, administered within 24 hours of commencing organ support in an intensive care unit. It was reported that anti-IL6 agents decreased hospital mortality and reduced progression to intubation, extracorporeal membrane oxygenation, or death. Another study investigating...
tocilizumab in unwell patients with COVID-19 did not show these favourable outcomes\textsuperscript{143} and a need for caution in the use of tocilizumab in unwell patients with COVID-19 has been proposed.\textsuperscript{144} Encouragingly, results from the RECOVERY trial\textsuperscript{45} investigating the use of tocilizumab in patients admitted to hospital with COVID-19 have shown that tocilizumab improved survival and other clinical outcomes in patients with hypoxia and systemic inflammation (C-reactive protein at or above 75 mg/l).\textsuperscript{136} These benefits were seen regardless of the level of respiratory support. Drug registries\textsuperscript{146,147} on the use of tocilizumab in pregnancy have limited numbers but show no evidence of harm. Tocilizumab is excreted in very low levels in breast milk.\textsuperscript{148} Any decision to treat pregnant or postnatal women with anti-IL6 agents should be taken by an MDT and, when feasible, in discussion with the woman.

Pregnant women can be enrolled in the RECOVERY trial.\textsuperscript{136} Where therapies or participation in trials are offered, they should also be considered for and offered to pregnant women.
6. Postnatal care
6. Postnatal care

Routine postnatal care for women in accordance with national guidelines and the RCOG guidance for maternity service organisation in areas of high-risk prevalence/local lockdown during the COVID-19 pandemic should be followed. As prevalence subsides, strategies will be needed to ensure that previous evidence-based services that have been put on hold or amended are reinstated.

6.1 How should neonatal care for the baby be provided during the COVID-19 pandemic?

Advice

• Women and their healthy babies should remain together in the immediate postpartum period, if they do not otherwise require maternal critical care or neonatal care.

• Women with suspected or confirmed COVID-19 should remain with their baby and be supported to practice skin-to-skin/kangaroo care, if the newborn does not require additional medical care at this time.

• Adopt a precautionary approach for a woman who has suspected or confirmed COVID-19 and whose baby needs to be cared for on the neonatal unit to minimise any risk of women-to-infant transmission; at the same time, involve parents in decisions, mitigating potential problems for the baby’s health and wellbeing and for breastfeeding, bonding and attachment.

• Women should be supported to make an informed decision about how they feed their baby. Women who choose to breastfeed should be supported to do so, even if they have probable or confirmed COVID-19.

• A risk and benefits discussion between neonatologists and families should take place to individualise care in babies who may be more susceptible to infection.

• Babies born to SARS-CoV-2-positive women should be cared for as per guidance from the Royal College of Paediatrics and Child Health (RCPCH).

• Specific guidance on neonatal resuscitation during the COVID-19 pandemic is available from the Resuscitation Council.

Summary of evidence and rationale for guidance

There are limited data to guide the neonatal care of babies of women who tested positive for SARS-CoV-2 in the third trimester. A prospective cohort study in the UK investigating SARS-CoV-2 infection in the first 28 days of life found that neonatal infection is uncommon.
(66 babies with confirmed SARS-CoV-2 infection [incidence 5.6 per 10,000 livebirths, 95% CI 4.3–7.1], of whom 28 [42%] had severe neonatal SARS-CoV-2 infection [incidence 2.4 per 10,000 livebirths, 95% CI 1.6–3.4]), and infection with neonatal admission following birth to a woman with perinatal SARS-CoV-2 infection was unlikely; consequently, this study supported guidance to avoid separation of woman and baby.

The RCPCH and the RCM have provided separate guidance on this topic,¹⁵¹,¹⁵² and the Resuscitation Council has produced various COVID-19 resources on newborn life support.

6.2 What should women and families be advised regarding infant feeding during the COVID-19 pandemic?

Advice

- Breastfeeding should be recommended to all women in line with usual guidance.

- Individualised support, advice and guidance on breastfeeding should be offered to all women who wish to breastfeed. Remote support for breastfeeding should be signposted to all women.

- Women and their families should be informed that infection with COVID-19 is not a contraindication to breastfeeding.

- Women and their families should be supported to make a fully informed choice on how to feed their baby. The risks and benefits of feeding the baby in close proximity to individuals with suspected or confirmed COVID-19 should be discussed.

- When a woman is not well enough to care for her own infant or where direct breastfeeding is not possible, the woman should be supported to express her breastmilk by hand or using a breast pump, and/or offer access to donor breast milk.

- The following RCPCH precautions should be taken to limit viral spread to the baby:
  - Wash hands before touching the baby, breast pump or bottles.
  - Avoid coughing or sneezing on the baby while feeding.
  - Consider wearing a face covering or fluid-resistant facemask while feeding or caring for the baby.

- Babies should not wear masks or other face coverings as they may risk suffocation.

- When women are expressing breastmilk in hospital, a dedicated breast pump should be used.
Adhere to recommendations for pump cleaning after each use.

- Adhere strictly to sterilisation guidance for babies who are bottle-fed with formula or expressed milk.
- Consider asking someone who is well to feed the baby.

Summary of evidence and rationale for guidance

The long term well-established benefits of breastfeeding are highly likely to outweigh any potential risks of transmission of the virus through breastmilk. A systematic review found that in 24 cases breastmilk tested negative for COVID-19; however, given the small number of cases, this evidence should be interpreted with caution. A cohort study demonstrated that both skin-to-skin and breastfeeding are not associated with increased neonatal infection with SARS-CoV-2. Similar findings exist in smaller studies which supports the guidance.

In light of the evidence to date, the benefits of breastfeeding outweigh any potential risks of transmission of the virus through breastmilk, and this is a view supported by the UNICEF UK Baby Friendly Initiative, which has been widely implemented in the UK.

The main risk of breastfeeding is the close contact between the baby and the woman, who is likely to share infective respiratory droplets.

Specific recommendations on minimising the risk of COVID-19 transmission when feeding babies has been developed by the RCPCH and RCM. The NHS has general guidance on sterilising bottles in order to protect babies against infections.

Face coverings are not appropriate for babies. The UK government advice for using face coverings is directed towards adults and children aged 11 and over.

6.3 What are the considerations for postnatal care for women and babies following admission with COVID-19?

General advice

- Postnatal care should be provided as per NICE CG37 Postnatal care up to 8 weeks after birth.
- Following childbirth, effective contraception should be discussed with and offered to all women prior to discharge from maternity services.

Advice

- All households should self-isolate at home for 14 days after birth of a baby to a woman with COVID-19.
• Women and their families should be advised about safe sleeping and a smoke-free environment, along with provision of clear advice about careful hand hygiene and infection control measures when caring for and feeding the baby.

• Families should be guided on how to identify signs of illness in their newborn or worsening of the woman’s symptoms, and should be provided with appropriate contact details if they have concerns or questions about their baby’s wellbeing. NHS leaflets, providing this information, are also available.

• Women should be advised that if they or their babies require readmission for postnatal obstetric or neonatal care during a period of self-isolation for suspected or confirmed COVID-19 they should telephone their local unit ahead of arrival.

• Women who have recently given birth and test positive for COVID-19 should receive all recommended advice, guidance and support in relation to their postnatal physical and mental health and wellbeing and care of their newborn baby. This includes necessary in-person assessments using appropriate PPE.

• In-person home or clinic appointments should be offered to allow an overall assessment of the physical and psychological health and wellbeing of the woman and her baby.

• In some areas, and where appropriate, some postnatal care will need to be via telephone or video link because of local infection rates and staff absence, but considerations should be made upon individual circumstances. This should be discussed with women and families.

• All pregnant women who have been hospitalised and have had confirmed COVID-19 should be offered thromboprophylaxis for 10 days following hospital discharge. A longer duration of thromboprophylaxis should be considered for women with persistent morbidity.

Summary of evidence and rationale for guidance

The RCPCH has published guidance on the neonatal care of babies born to women with COVID-19. The advice for households to isolate for 14 days after the birth of a baby born to a woman who is infected with SARS-CoV-2 is to ensure a full period of isolation in case of incubation of the virus in the baby. These advice statements have been extrapolated from the RCPCH guidance and expert consensus opinion.

Guidance on the provision of contraception by maternity services after childbirth during the COVID-19 pandemic has been produced jointly by the Faculty of Sexual and Reproductive Health, the RCOG and the RCM.

Recommendations on postnatal care should be maintained as per the NICE CG37 Postnatal care up to 8 weeks after birth.
Acknowledgments

The RCOG COVID-19 guidance cell is comprised of:

**Dr Edward Morris** (President, RCOG), **Professor Tim Draycott** (Vice President for Clinical Quality, RCOG), **Dr Pat O’Brien** (Vice President for Membership, RCOG), **Dr Andrew Thomson** (COVID Guidance Development Lead, RCOG), **Dr Mary Ross-Davie** (Director for Scotland, RCM), **Dr Corinne Love** (Senior Medical Officer, Obstetrics, the Scottish Government), **Dr Jennifer Jardine** (Clinical Fellow, RCOG), **Dr Sayaka Okano** (Honorary Clinical Fellow, RCOG), **Dr Michael Shea** (Honorary Clinical Fellow, RCOG), **Lara Waite** (Clinical Midwifery Fellow, RCOG), **Dr Sophie Relph** (Clinical Fellow, RCOG), **Louise Thomas** (Head of Quality Improvement, RCOG), **Emma Gilgunn-Jones** (Director of Media and PR, RCOG), **Jenny Priest** (Director of Policy and Public Affairs, RCOG), **Farrah Pradhan** (Interim Business Manager, RCOG), **Michelle Sadler** (Guidance Editorial Manager, RCOG), **Sophie Cooper** (Business Coordinator, RCOG) and **Stephen Hall** (Political Advisor to the President, RCOG).

These individuals were, but are not currently, members of the guidance cell and have contributed to earlier versions of this document: **Dr Jahnavi Daru** (Honorary Clinical Fellow, RCOG), **Dr Christine Ekechi** (Honorary Clinical Fellow, RCOG), **Dr Gemma Goodyear** (Clinical Fellow, RCOG), **Dr Anushka Tirlapur** (Honorary Clinical Fellow, RCOG), **Anita Powell** (Senior Director for Clinical Quality, RCOG), **Gemma Thurston** (Business Manager, RCOG) and **Gozde Zorlu** (Media and PR Manager, RCOG).

The following external subject experts contributed to the section on VTE: **Professor Beverley Hunt**, **Professor Catherine Nelson-Piercy**, **Professor Rezan Abdulkadir**, **Dr Peter MacCallum**, **Dr Louise Bowles** and **Dr Shohreh Beski**; and to the section on Managing Clinical Deterioration of COVID-19: **Professor Catherine Nelson-Piercy**, **Dr Margaret Blott**, **Dr Arlene Wise** and **Professor Lucy Chappell** and to Appendices V and VI: **Dr Anita Banerjee** and **Dr Guy Glover** and staff at Guy’s and St Thomas’ NHS Foundation Trust who originally developed these plans.

We also wish to acknowledge the contributions of:

**Professor Russell Viner** and **Dr David Evans** on behalf of the Royal College of Paediatrics and Child Health, **Dr Fiona Donald** and **Dr Nuala Lucas** on behalf of the Obstetric Anaesthetists Association and Royal College of Anaesthetists, **Dr Giles Berrisford** on behalf of the Royal College of Psychiatrists, **Professor Asma Khalil**, **Dr Lucy Mackillop**, **Dr Charlotte Frise**, **Dr Toni Hazell**, **Dr Ed Mullins**, **Dr Benjamin Black**, **Zeenath Uddin**, and colleagues from the **RCOG Digital, External Affairs** and **Clinical Quality teams**.
Appendices
## Appendix 1: Summary of previous updates

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Summary of changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>12.3.20</td>
<td>1.2: At the time of writing, Public Health Wales are aligning with Public Health England on case definitions, assessment, infection prevention and control and testing. We will update <a href="#">this guidance</a> if this changes.</td>
</tr>
<tr>
<td>2</td>
<td>13.3.20</td>
<td>2.2: Updated to reflect PHE and health protection advice as per 13.03.20, in particular to use online symptom checkers and to treat all individuals with symptoms as possibly having COVID-19.</td>
</tr>
<tr>
<td>2</td>
<td>13.3.20</td>
<td>3.2: Sentence on who to test updated to reflect advice to test women with symptoms suggestive of COVID-19 who require admission.</td>
</tr>
<tr>
<td>2</td>
<td>13.3.20</td>
<td>3.6.4 and 3.6.5: Updated to suggest considering delay of elective caesarean birth or induction for women with symptoms suggestive of COVID-19 as well as those with confirmed COVID-19.</td>
</tr>
<tr>
<td>2</td>
<td>13.3.20</td>
<td>3.8: Infant feeding modified from recommendation to wear a face mask to try and avoid coughing or sneezing on the baby, and consider wearing face mask where available.</td>
</tr>
<tr>
<td>2</td>
<td>13.3.20</td>
<td>5 (new): New section - Advice for pregnant healthcare professionals.</td>
</tr>
<tr>
<td>2</td>
<td>13.3.20</td>
<td>Appendix 1: Flow chart amended to reflect modified PHE guidance.</td>
</tr>
<tr>
<td>3</td>
<td>17.3.20</td>
<td>2: Advice for Health Professionals to share with Pregnant Women updated to reflect current guidelines.</td>
</tr>
<tr>
<td>3</td>
<td>17.3.20</td>
<td>3: New section added on Advice for all midwifery and obstetric services.</td>
</tr>
<tr>
<td>3</td>
<td>17.3.20</td>
<td>4.1: General advice to services providing care to pregnant women updated to reflect advice from chief medical officer on 16/3/20.</td>
</tr>
<tr>
<td>3</td>
<td>14.3.20</td>
<td>4.1: Advice on cleaning ultrasound equipment added, and reference added.</td>
</tr>
<tr>
<td>3</td>
<td>17.3.20</td>
<td>4.5: Linked to new national guidance on the actions required when a COVID-19 case was not diagnosed on admission.</td>
</tr>
<tr>
<td>3</td>
<td>17.3.20</td>
<td>4.6.2: Recommendations added: There is evidence of household clustering and household co-infection. Asymptomatic birth partners should be treated as possibly infected and asked to wear a mask and wash their hands frequently. If symptomatic, birth partners should remain in isolation and not attend the unit. The use of birthing pools in hospital should be avoided in suspected or confirmed cases, given evidence of transmission in faeces and the inability to use adequate protection equipment for healthcare staff during water birth.</td>
</tr>
<tr>
<td></td>
<td>Date</td>
<td>Section</td>
</tr>
<tr>
<td>---</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td>3</td>
<td>17.3.20</td>
<td>4.6.2</td>
</tr>
<tr>
<td>3</td>
<td>17.3.20</td>
<td>4.6.4</td>
</tr>
<tr>
<td>3</td>
<td>17.3.20</td>
<td>4.7.1</td>
</tr>
<tr>
<td>3</td>
<td>17.3.20</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>17.3.20</td>
<td>4.7.1</td>
</tr>
<tr>
<td>3</td>
<td>17.3.20</td>
<td>6</td>
</tr>
<tr>
<td>4</td>
<td>21.3.20</td>
<td>6</td>
</tr>
<tr>
<td>4</td>
<td>21.3.20</td>
<td>1.3-1.4</td>
</tr>
<tr>
<td>4</td>
<td>21.3.20</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>21.3.20</td>
<td>4.7</td>
</tr>
<tr>
<td>4</td>
<td>21.3.20</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>21.3.20</td>
<td>All</td>
</tr>
<tr>
<td>4</td>
<td>21.3.20</td>
<td>6</td>
</tr>
<tr>
<td>4.1</td>
<td>26.3.20</td>
<td>Chapter 6</td>
</tr>
<tr>
<td>4.1</td>
<td>26.3.20</td>
<td>4.7.3</td>
</tr>
<tr>
<td>5</td>
<td>28.3.20</td>
<td>1.3: Section updated to include new evidence on possible vertical transmission.</td>
</tr>
<tr>
<td>---</td>
<td>---------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>5</td>
<td>28.3.20</td>
<td>2.2: Sentence added on the major new measures announced by government for pregnant women with co-existing significant congenital or acquired heart disease.</td>
</tr>
<tr>
<td>5</td>
<td>28.3.20</td>
<td>2.3: Section updated to emphasise the need to attend maternity care.</td>
</tr>
<tr>
<td>5</td>
<td>28.3.20</td>
<td>3: General advice for antenatal care extended to include considerations for vulnerable women. Section also added on general advice regarding intrapartum services.</td>
</tr>
<tr>
<td>5</td>
<td>28.3.20</td>
<td>3.1: Specific advice added regarding the cessation of carbon monoxide monitoring in pregnancy, following advice from the National Centre for Smoking Cessation and Training.</td>
</tr>
<tr>
<td>5</td>
<td>28.3.20</td>
<td>4: Scotland specific links to Health Protection Scotland removed after confirmation from the Scottish government that National links from gov.uk should be used.</td>
</tr>
<tr>
<td>5</td>
<td>28.3.20</td>
<td>4.3.6: Scotland specific links to Health Protection Scotland removed after confirmation from the Scottish government that National links from gov.uk should be used.</td>
</tr>
<tr>
<td>5</td>
<td>28.3.20</td>
<td>4.7.3 and 4.76: Advice on PPE considerations for caesarean birth and general advice for obstetric theatres moved to new section ‘Specific peri-operative advice for pregnant women with suspected/confirmed COVID-19 requiring surgical intervention’.</td>
</tr>
<tr>
<td>5</td>
<td>28.3.20</td>
<td>4.8.1: Reference made to new guidance published by NICE on the management of patients with COVID-19 in critical care.</td>
</tr>
<tr>
<td>5</td>
<td>28.3.20</td>
<td>4.9.2: Section edited to make infant feeding recommendations to any caregiver, not just to the mother.</td>
</tr>
<tr>
<td>5</td>
<td>28.3.20</td>
<td>4.10: New section on ‘Specific peri-operative advice for pregnant women with suspected/confirmed COVID-19 requiring surgical intervention’.</td>
</tr>
<tr>
<td>5</td>
<td>28.3.20</td>
<td>5.1: Correction of an error in the title to clarify that this section refers to the care of women recovering from suspected (not confirmed) COVID-19 for which hospitalisation was not required.</td>
</tr>
<tr>
<td>6</td>
<td>3.4.20</td>
<td>Throughout: References to the new RCOG guidance on (1) antenatal and postnatal services (2) antenatal screening (3) fetal medicine services (4) maternal medicine services and (5) self-monitoring of blood pressure, have been added throughout the document.</td>
</tr>
<tr>
<td>6</td>
<td>3.4.20</td>
<td>1.2: New resources signposted on current UK and international disease incidence.</td>
</tr>
<tr>
<td>6</td>
<td>3.4.20</td>
<td>1.4: Sentence reporting that there are ‘no reported maternal deaths from COVID-19’ removed because there was recently a possible maternal death reported in tabloid media. There is not any robust evidence to amend this statement or report confidently in the guideline.</td>
</tr>
<tr>
<td>6</td>
<td>3.4.20</td>
<td>3.2: Addition of new advice on screening birth partners for recent possible symptoms of COVID-19 when they attend the maternity unit. In addition, suggestion of information to give the birth partner about what is expected of them whilst they are in the hospital, to assist staff in reducing the risk of infection transmission and to assist with communication when birth partners accompany women into operating theatres.</td>
</tr>
<tr>
<td>6</td>
<td>3.4.20</td>
<td>3.4: Moved to section 3.2.</td>
</tr>
<tr>
<td>6</td>
<td>3.4.20</td>
<td>3.5: New section on maternal mental wellbeing during the pandemic.</td>
</tr>
<tr>
<td>6</td>
<td>3.4.20</td>
<td>4.1 The previous section 4.2 was repetitive of section 3.1 and so has been removed. Sections 4.2 onwards have been re-numbered.</td>
</tr>
<tr>
<td>Page</td>
<td>Date</td>
<td>Section</td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
<td>---------</td>
</tr>
<tr>
<td>6</td>
<td>3.4.20</td>
<td>4.3</td>
</tr>
<tr>
<td>6</td>
<td>3.4.20</td>
<td>4.9</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>1.4</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>1.4</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>2.3</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>3.1</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>3.2</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>3.2</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>3.3</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>4.2</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>4.2</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>4.3.1</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>4.4</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>4.6.1</td>
</tr>
<tr>
<td>7</td>
<td>9.4.20</td>
<td>4.7.2</td>
</tr>
<tr>
<td>8</td>
<td>17.4.20</td>
<td>1: New paragraph on the quality of the available evidence and resultant classification of the advice.</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>8</td>
<td>17.4.20</td>
<td>1.4: New evidence included on the risk of COVID-19 in the woman, including a case series of pregnant women attending two maternity units in New York, who were screened for COVID-19 on arrival, the inclusion of the first report of maternal death directly attributed to COVID-19 in scientific literature and an update to the ICNARC data.</td>
</tr>
<tr>
<td>8</td>
<td>17.4.20</td>
<td>4.2, 4.5.2 &amp; 4.6.2: Restructured, including some new subtitles to organise and break up the text.</td>
</tr>
<tr>
<td>8</td>
<td>17.4.20</td>
<td>4.3.1: Renamed ‘risk of venous thromboembolism’.</td>
</tr>
<tr>
<td>8</td>
<td>17.4.20</td>
<td>4.6: Section restructured for clarity.</td>
</tr>
<tr>
<td>8</td>
<td>17.4.20</td>
<td>4.7 and 4.8: Re-ordered the two sections within the text so that considerations for birth are written before considerations for neonatal and postnatal care.</td>
</tr>
<tr>
<td>8</td>
<td>17.4.20</td>
<td>5.3: Section re-structured. Also includes clarification that the recommendation for 10 days postnatal LMWH is regardless of mode of birth.</td>
</tr>
<tr>
<td>8</td>
<td>17.4.20</td>
<td>Appendix 2: Table of previous updates moved to appendix 3.</td>
</tr>
<tr>
<td>8</td>
<td>17.4.20</td>
<td>Appendix 3: New information on considerations when caring for women with suspected/confirmed COVID-19 during labour and birth.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>1: Aims updated to include: The provision of safe, woman-centred care to women who are pregnant, give birth or are in the early postnatal period during the COVID-19 pandemic.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>1.3: Updated information on possibility of vertical transmission to state that there are serious limitations to the available evidence.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>1.4: Updated with emerging evidence on increased risk from COVID-19 to individuals with black, Asian and minority ethnic (BAME) background.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>2: Information to share with pregnant women and their families has been removed from the guidance. All this information is also available in the RCOG information for pregnant women and their families in the COVID-19 hub. All subsequent sections have been renumbered.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>3.1 (Now 2.1): Added paragraph about reducing transmission between staff.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>3.2 (Now 2.2): Statement and recommendations added:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Emerging evidence suggests that individuals of black and minority ethnic (BAME) background may be at higher risk of developing severe complications of COVID-19. This may equally apply to pregnant women. We therefore advise:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Women of BAME background should be opportunistically advised that they may be at higher risk of complications of COVID-19, and advised to seek help early if they are concerned about their health.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clinicians should be aware of this increased risk, and have a lower threshold to review, admit and consider multidisciplinary escalation in women of BAME background.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>2.2: Removed statement that further guidance on remote consultations will be published soon, and provided reference to RCM/RCOG guidance on antenatal and postnatal care.</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>2.3: Changed the statement that units should consider reducing provision of induction of labour for indications that are not ‘strictly necessary’, to units should consider reducing induction of labour where this is not ‘medically indicated’.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>3.3 (Now 2.3): Reference to NHS England ‘Clinical guide for the temporary reorganisation of intrapartum maternity care during the coronavirus pandemic’ added.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>3.3 (Now 2.3): Statement added: ‘Care should be taken to maintain safe services which continue to offer women support and choice as far as possible at this time. In particular, women should continue to be encouraged to contact their maternity unit with concerns about their or their baby’s wellbeing. Justification should be provided for any service rationalisation required.’</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>3.3 (Now 2.3): Statement added: ‘When reorganising services, maternity units should be particularly cognisant of emerging evidence that black, Asian and minority ethnic group (BAME) individuals are at particular risk of developing severe and life-threatening COVID-19. There is already extensive evidence on the inequality of experience and outcomes for BAME women during pregnancy and birth in the UK. Particular consideration should be given to the experience of women of BAME background and of lower socioeconomic status, when evaluating the potential or actual impact of any service change.’</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>4.6 (Now 3.6): Recommendation to be aware that myocardial injury is common among individuals with COVID-19, and reference added to NICE Guidance on diagnosis of myocardial injury in patients with suspected or confirmed COVID-19.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>4.5.2 (Now 3.5.2): Care in labour: Risk of venous thromboembolism. Clarification added that all women with suspected or confirmed COVID-19 should be discharged with 10 days’ supply of prophylactic LMWH.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>4.4 (Now 3.4): Women who develop new symptoms of COVID-19 during admission: Statement added that prophylaxis for venous thromboembolism should be considered and prescribed unless contraindicated.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>4.6 (Now 3.6): Title change from ‘Additional considerations in women with moderate/severe symptoms’ to ‘Women with suspected or confirmed COVID-19 and moderate/severe symptoms’, to reflect that this includes information relevant to pregnant women admitted with COVID-19 outside of obstetric services.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>4.6 (Now 3.6): Recommendation added: ‘Prophylaxis for venous thromboembolism should be prescribed during admission unless contraindicated. At the time of discharge from hospital following a period of care for confirmed COVID-19 infection, all women should be prescribed at least 10 days of prophylactic LMWH.’ This is consistent with recommendations already made elsewhere in previous versions of this document.</td>
</tr>
<tr>
<td>9</td>
<td>13.5.20</td>
<td>4.6 (Now 3.6): Changed statement ‘Consider bacterial infection if the white blood cell count is raised (lymphocytes usually normal or low with COVID-19) and commence antibiotics’ to ‘Bacterial infection is an important differential diagnosis to COVID-19 infection. We advise blood cultures and a low threshold for antibiotics at presentation, with early review and rationalisation of antibiotics if COVID-19 is confirmed.’</td>
</tr>
</tbody>
</table>
The following Version 10 summary of changes includes an additional column to reflect significant restructure changes between version 9 and 10 of this guidance.

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary of changes</th>
<th>Section content from v9</th>
<th>Location in v10 update</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.6.20</td>
<td>Introduction</td>
<td>Now incorporates the following sections from v9:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Purpose and scope</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Identification and assessment of evidence</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Epidemiology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Transmission</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Effect of COVID-19 on pregnant women</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Risk factors for hospital admission with COVID-19</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Effect of COVID-19 on the fetus</td>
<td></td>
</tr>
<tr>
<td>4.6.20</td>
<td>Antenatal care during the COVID-19</td>
<td>2.2. General advice regarding the continued provision of antenatal and postnatal services</td>
<td>2.1 What are the considerations for organisation of antenatal care during the COVID-19 pandemic?</td>
</tr>
<tr>
<td></td>
<td>pandemic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.6.20</td>
<td>Antenatal care during the COVID-19</td>
<td>2.3 General advice regarding possible service modifications during COVID-19</td>
<td>2.2 What are the considerations for antenatal appointments?</td>
</tr>
<tr>
<td></td>
<td>pandemic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.6.20</td>
<td>Antenatal care during the COVID-19</td>
<td>2.6 Smoking cessation and carbon monoxide monitoring in pregnancy</td>
<td>2.3 What are the considerations for antenatal appointments?</td>
</tr>
<tr>
<td></td>
<td>pandemic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.6.20</td>
<td>Antenatal care during the COVID-19</td>
<td>2.5 Maternal mental wellbeing</td>
<td>2.2 What are the considerations for antenatal appointments?</td>
</tr>
<tr>
<td></td>
<td>pandemic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.6.20</td>
<td>Antenatal care during the COVID-19</td>
<td>3.1 General advice for services providing care to pregnant women with suspected or confirmed COVID-19, where hospital attendance is necessary</td>
<td>2.3 How should women with suspected or confirmed COVID-19 needing hospital attendance or advice be cared for?</td>
</tr>
<tr>
<td>4.6.20</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>3.2 Women with unconfirmed COVID-19 but symptoms suggestive of possible infection</td>
<td>2.3 How should women with suspected or confirmed COVID-19 needing hospital attendance or advice be cared for?</td>
</tr>
<tr>
<td>4.6.20</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>3.3.3 Attendance for unscheduled/urgent antenatal care in women with suspected or confirmed COVID-19</td>
<td>2.3 How should women with suspected or confirmed COVID-19 needing hospital attendance or advice be cared for?</td>
</tr>
<tr>
<td>4.6.20</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>4.1 Antenatal care for pregnant women following self-isolation for symptoms suggestive of COVID-19</td>
<td>2.4 What are the considerations for antenatal care for women who have recovered from COVID-19?</td>
</tr>
<tr>
<td>4.6.20</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>4.2 Antenatal care for pregnant women following hospitalisation for confirmed COVID-19 illness</td>
<td>2.4 What are the considerations for antenatal care for women who have recovered from COVID-19?</td>
</tr>
<tr>
<td>4.6.20</td>
<td>Venous thromboembolism prevention</td>
<td>3.3.3 Risk of venous-thromboembolism</td>
<td>3.1 How should prevention of venous thromboembolism during the COVID-19 pandemic be addressed?</td>
</tr>
<tr>
<td>4.6.20</td>
<td>Venous thromboembolism prevention</td>
<td>3.4 Women who develop new symptoms of COVID-19 during admission (antenatal, intrapartum or postnatal)</td>
<td>3.1 How should prevention of venous thromboembolism during the COVID-19 pandemic be addressed?</td>
</tr>
<tr>
<td>4.6.20</td>
<td>Labour and birth</td>
<td>2.4 General advice regarding intrapartum services</td>
<td>4.4 What about birth partners during the COVID-19 pandemic?</td>
</tr>
<tr>
<td>4.6.20</td>
<td>Labour and birth</td>
<td>Not in version 9</td>
<td>New section in version 10: 4.1 What are the considerations for labour and birth in asymptomatic women who test or have tested positive for SARS-CoV-2?</td>
</tr>
<tr>
<td>4.6.20</td>
<td>Labour and birth</td>
<td>3.5 Women attending for intrapartum care with suspected or confirmed COVID-19</td>
<td>4.2 How should a woman with suspected/confirmed COVID-19 be looked after in labour if they are symptomatic?</td>
</tr>
<tr>
<td>--------</td>
<td>------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4.5 What informed discussions should take place with women regarding timing and mode of birth during the COVID-19 pandemic?</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4.6 What are the specific considerations for labour analgesia or anaesthesia?</td>
</tr>
<tr>
<td>4.6.20</td>
<td>Labour and birth</td>
<td>3.7 Specific peri-operative advice for healthcare professionals caring for pregnant women with suspected/confirmed COVID-19 who require surgical intervention</td>
<td>4.8 How should obstetric theatres be managed during the COVID-19 pandemic?</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4.7 What personal protective equipment is recommended when caring for women during labour and birth?</td>
</tr>
<tr>
<td>4.6.20</td>
<td>Postnatal</td>
<td>3.8 Neonatal care</td>
<td>6.1 How should neonatal care for the baby be provided during the COVID-19 pandemic?</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6.2 What should parents/carers be advised regarding infant feeding during the COVID-19 pandemic?</td>
</tr>
<tr>
<td>4.6.20</td>
<td>Postnatal</td>
<td>4.3 Postnatal care for pregnant women immediately following hospitalisation for confirmed COVID-19 illness</td>
<td>6.3 What are the considerations for postnatal care for women and babies following admission with COVID-19?</td>
</tr>
<tr>
<td>10.1</td>
<td>19.6.20</td>
<td>1.1: Removal of ‘MERS, Middle East Respiratory Syndrome’ from the literature search strategy since it has not resulted in any new references since the first search.</td>
<td></td>
</tr>
<tr>
<td>10.1</td>
<td>19.6.20</td>
<td>1.4: UKOSS reference changed to the published article in The BMJ.</td>
<td></td>
</tr>
<tr>
<td>10.1</td>
<td>19.6.20</td>
<td>2.2: Advice on face masks changed to reflect national guidance from NHS England.</td>
<td></td>
</tr>
<tr>
<td>10.1</td>
<td>19.6.20</td>
<td>4.4: Advice on number of visitors and/or birth partners for hospital inpatients changed to reflect national guidance from NHS England.</td>
<td></td>
</tr>
<tr>
<td>10.1</td>
<td>19.6.20</td>
<td>5.2: Advice for women who are clinically deteriorating modified to include government recommendations based on the interim results of the RECOVERY trial.</td>
<td></td>
</tr>
<tr>
<td>10.1</td>
<td>19.6.20</td>
<td>6.2: Specified that babies should not be advised to wear face masks because of the risk of suffocation.</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>24.7.20</td>
<td>1.1: Updated methodology about search strategies and the review process.</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>24.7.20</td>
<td>1.3: Updated evidence that there is a low rate of vertical transmission and possible transplacental transmission.</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>24.7.20</td>
<td>1.4: Updated evidence that pregnant women are not necessarily more susceptible to SARS-CoV-2 than the general population.</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>24.7.20</td>
<td>1.5: Updated evidence identifying the risk factors of Black, Asian and minority ethnicity (BAME), obesity and comorbidities in pregnant women admitted with COVID-19.</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>24.7.20</td>
<td>1.6: Updated evidence on possible fetal growth restriction associated with COVID-19.</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>24.7.20</td>
<td>2.1: Updated advice:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Units should employ teleconferencing and videoconferencing where possible and consider which appointments can be most appropriately conducted remotely, especially in areas of local lockdown to minimise hospital attendance.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Particular consideration should be given to pregnant women who are ‘shielding’ or have been ‘shielding’. Shared waiting areas should be avoided.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Units should appoint a named midwife or consultant to coordinate care for women forced to miss appointments due to self-isolation or a positive test.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Missed appointments should be reviewed and either rescheduled if a face-to-face review is necessary or converted to a remote appointment.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Evidence added on the possible increased incidence of stillbirths in women without symptoms suggestive of COVID-19 in the pandemic compared to pre-pandemic periods.</td>
<td></td>
</tr>
</tbody>
</table>
### 2.2: Updated advice:

- Evidence suggests that individuals of BAME background are at higher risk of developing severe complications of COVID-19. This also applies for pregnant women. We therefore advise that:
  - Women of BAME background should be advised that they may be at higher risk of complications of COVID-19; and encouraged to seek advice without delay if they are concerned about their health.
  - Clinicians should maintain face-to-face appointments with women when there are safeguarding concerns in order to provide extra support.
  - It is recommended that women should continue to take folic acid and vitamin D supplements as per national recommendations.
  - If women or their families express concerns about their mental health or ‘red flag’ symptoms such as suicidal thoughts or sudden mood changes they should be supported to access urgent care by healthcare providers signposting or referring appropriately.

### 2.3: Amended advice:

- Visitors to isolation rooms or ward cohort bays should be kept to a minimum and follow local hospital visitor policies.

### 4.1: Amended advice:

- For asymptomatic women who test positive for SARS-CoV-2 on admission, continuous electronic fetal monitoring (CEFM) during labour using cardiotocography (CTG) is not recommended solely for this reason, and should only be used if it is required for another reason (e.g. previous caesarean birth).  
  - Fetal monitoring options should be discussed with the woman, acknowledging the current uncertainties in the care of women who are asymptomatic with a positive test for SARS-CoV2.

### 4.2: Additional advice:

- There are no contraindications to performing a fetal blood sample or using fetal scalp electrodes.

Advice on waterbirths has been revised and moved to (new) section 4.6.

### 4.3: Amended advice:

- Informed discussions with women about fetal monitoring should acknowledge that evidence of fetal distress is based on small numbers of babies born to women symptomatic of COVID-19 and theoretical risks extrapolated from pregnancies affected by fetal growth restriction in women with other coronaviruses.
## 4.4: Amended advice:
- If birth partners are symptomatic or in a period of self-isolation for confirmed SARS-CoV-2 infection, they should remain in self-isolation at home and not attend the unit.

Advice removed: on birth partners being asked to remain by the woman’s bedside and not to walk around the ward/hospital.

## 4.5: Amended advice:
- Women and their families should be aware that donning PPE for emergency caesarean births is time-consuming but essential, and that this may impact on the time it takes to assist in the birth of the baby and potentially result in an adverse outcome. This should be taken into account during decision-making and ideally discussed during birth planning.

Removed advice on the use of birthing pools in hospital for women with suspected or confirmed cases of COVID-19.

Updated evidence about vertical transmission and data about donning PPE.

## 4.6: New section on ‘What are the considerations regarding waterbirth?’

## 4.8: Amended advice:
- Healthcare professionals are advised to follow national recommendations on the use of personal protective equipment in clinical settings.

## 4.10: New section ‘What are the considerations for bereavement care during the COVID-19 pandemic?’

## 5.1: Amended advice:
- Women should be offered testing for COVID-19 if they meet the inpatient or community PHE criteria.

## 5.2: Updated advice:
- A designated team member should be responsible for regularly updating the woman’s family about her progress, utilising interpreting services where necessary.
- Thrombocytopenia is associated with severe COVID-19. For women with thrombocytopenia (platelets <50 x 10^9/L) stop aspirin prophylaxis and thromboprophylaxis and seek haematology advice.
- Consider using mechanical aids (such as intermittent calf compressors) if thromboprophylaxis is paused secondary to thrombocytopenia.
- Consider the use of antiviral medications, such as remdesivir, that have been shown to be potentially beneficial in COVID-19.
- If there is clinical uncertainty in whether to offer a therapy to a pregnant woman, seek advice through maternal medicine networks.
### 6.1: Added advice:

- Women with suspected or confirmed COVID-19 should be supported and enabled to remain together with their babies when the woman is well enough, and to practice skin-to-skin/kangaroo care, if the newborn baby does not require additional medical care at this time.

- For a woman who has suspected or confirmed COVID-19 and whose baby needs to be cared for on the neonatal unit, a precautionary approach should be adopted to minimise any risk of women-to-infant transmission; at the same time, steps should be taken to involve parents in decisions, mitigating potential problems for the baby’s health and well-being and for breastfeeding and attachment.

- Women who have suspected, probable or confirmed COVID-19 should be enabled and supported to breastfeed, if this is what they choose.

### 6.2: Title amended to: What should women and families be advised regarding infant feeding during the COVID-19 pandemic?

**Added advice**

- Breastfeeding is recommended for all women and newborn infants.

- Support, advice and guidance on breastfeeding should be provided to all women who choose to breastfeed.

- When a woman is not well enough to care for her own infant or where direct breastfeeding is not possible, she should be supported to express her breastmilk by hand expression or by pump, and/or be offered access to donor breast milk.

### 6.3: Added advice:

- New mothers with COVID-19 still require all recommended advice, guidance and support in relation to their postnatal physical and mental health and wellbeing and care of their newborn.

- Postnatal care should be provided as per national guidance. Face-to-face home or clinic appointments are required to provide physical checks and the offer of screening, including any wound examinations from caesarean births/assisted births, the newborn blood spot test and checking the weight of the baby. In some areas, and where appropriate, some postnatal care will need to be via virtual appointments using telephone or video link due to local infection rates and staff absence but considerations need to be made upon individual circumstances. This needs to be communicated to women and families.

### Throughout: Comprehensive editorial review resulting in rewording and minor changes which do not affect meaning. Any changes to meaning and recommendations are detailed elsewhere in this table of changes.

### 1.2-1.7 Summary of evidence: Comprehensively updated and rewritten to incorporate changes to evidence base, in particular the MBRRACE Rapid Report and recent systematic reviews.
### 1.4 Antenatal care:

**Recommendations added:**

- The NICE recommended schedule of antenatal care should be offered in full wherever possible. These appointments should be offered in-person as far as possible, with particular attention to those from BAME communities or those living with medical, social or psychological conditions that make them higher risk.

- Appropriate screening for diabetes in pregnancy should be provided, following NICE guidance as far as possible, with awareness that changes in screening provision may be associated with a reduction in the detection of milder cases of gestational diabetes.

- Open access for pregnant women to day assessment and triage services should be maintained. Women should be actively encouraged to attend if they have concerns about their or their baby’s wellbeing.

- Continuity of carer should be maintained wherever possible, particularly where this is offered to women from vulnerable groups who may also be at greater risk from COVID-19.

### 2.2: Title changed for ‘what are the considerations for antenatal appointments?’ to ‘what are the considerations for antenatal appointments and advice for pregnant women?’

**Recommendations added:**

- Women should be advised that vaccination against influenza is safe at all gestations of pregnancy and is recommended to protect both the woman and baby from the adverse effects of becoming seriously ill with flu during pregnancy. During the COVID-19 pandemic, it is particularly important that pregnant women take up the influenza vaccine to reduce their risk of contracting flu.

- Appointments where physical examination is not required and where there are no additional risk factors are most appropriate to be conducted by virtual means.

- Services should establish triage processes to ensure that women with mental health concerns can be appropriately assessed.

**Recommendations removed**

- Virtual consultations should be encouraged where appropriate to minimise contact in person, however traditional in-person appointments may be more effective, especially when interpreters are required.
<table>
<thead>
<tr>
<th></th>
<th>Date</th>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>14.10.20</td>
<td>3.1 Thromboembolism</td>
<td>Supporting statement updated with reference to MBRRACE rapid report.</td>
</tr>
<tr>
<td>12</td>
<td>14.10.20</td>
<td>4.1 Labour and birth</td>
<td>Recommendations updated to reflect national policy change to 10 days isolation following a positive test for COVID-19.</td>
</tr>
<tr>
<td>12</td>
<td>14.10.20</td>
<td>4.4 Birth partners</td>
<td>Recommendations revised to:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• On attendance at the maternity unit, all birth partners should be asked whether they have experienced any symptoms suggestive of COVID-19 in the preceding 14 days, e.g. fever, acute persistent cough, changes in or loss of sense of smell (anosmia) or taste.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- If they have had symptoms within the last 10 days, they should be asked to leave the maternity unit immediately and self-isolate at home, unless they have had a negative test result for coronavirus since symptom onset</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- If they have had a fever within the last 48 hours, they should be asked to leave the maternity unit immediately and self-isolate at home, regardless of their test result.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Asymptomatic birth partners, not otherwise advised to be self-isolating, should be permitted to stay with the woman throughout labour and birth, unless the birth occurs under general anaesthetic. Further guidance about access to maternity services for birth partners and other supportive adults has been published by the NHS, and should be followed as far as possible.</td>
</tr>
<tr>
<td>12</td>
<td>14.10.20</td>
<td>4.6 Water birth</td>
<td>Supporting statement updated to reflect evidence review by the UK Infection Prevention and Control Cell.</td>
</tr>
<tr>
<td>12</td>
<td>14.10.20</td>
<td>6.3 Postnatal care</td>
<td>Recommendation revised to clarify that postnatal women who have tested positive for COVID-19, while required to isolate along with their households for 14 days, should still receive necessary in-person postnatal care.</td>
</tr>
<tr>
<td>12</td>
<td>14.10.20</td>
<td>Appendix II</td>
<td>Updated to reflect updates to document.</td>
</tr>
</tbody>
</table>
## Appendix II: Key considerations when caring for symptomatic women with suspected or confirmed COVID-19

### Setting for birth
- If homebirth or birth in a midwifery-led unit is planned, a discussion should be initiated with the woman regarding the potentially increased risk of fetal compromise in active phase of labour if symptomatic with SARS-CoV-2. Attending an obstetric unit, where the baby can be monitored using continuous electronic fetal monitoring (CEFM), should be recommended for birth.

### Timing for birth
- A positive COVID-19 result in an otherwise well woman, when there is also no evidence of fetal compromise, is not an indication to expedite birth.

  - Induction of labour (IOL) is associated with longer periods of inpatient stay than for spontaneous onset of labour.

  - Review the indication for IOL and consider whether the likely benefits outweigh possible risks. Where possible, review the provision and possibility of outpatient IOL.

  - For women who are currently in a period of self-isolation because of suspected COVID-19 in themselves or a household contact, an individual assessment should be made to determine whether it is safe to delay scheduled appointments for preoperative care and elective caesarean birth or IOL if planned to occur during their period of self-isolation.

  - The individualised assessment should consider the urgency of the birth and the risk of infectious transmission to other women, healthcare workers and, postnatally, to her baby.

### Mode of birth
- There is currently no evidence to favour one mode of birth over another in women who are SARS-CoV-2 positive, so mode of birth should be discussed with the woman, taking into consideration her preferences and any obstetric indications for intervention.

  - Mode of birth should not be influenced by the presence of COVID-19, unless the woman’s respiratory condition demands urgent intervention for birth.

  - Water birth is not contraindicated for women who are asymptomatic of COVID-19 and presumed or confirmed SARS-CoV-2 negative, providing adequate PPE can be worn by those providing care. For women who are symptomatic of COVID-19 with a cough, fever or feeling unwell, labour and birth in water is not recommended.
For women who are asymptomatic of COVID-19 but test positive for SARS-CoV-2, there is inadequate evidence about the risk of transmission in water. Advice should be sought from infection prevention and control authorities about waterbirth in these circumstances.

Women with worsening symptoms, or who are becoming exhausted, should be offered personalised information so that they can make an informed decision about expediting birth.

In case of deterioration in the woman’s symptoms, an individual assessment should be made regarding the risks and benefits of continuing the labour versus proceeding to emergency caesarean birth, if this is likely to assist efforts to resuscitate the woman.

Donning PPE is time-consuming. For emergency caesarean births, this may impact on the decision to birth interval but it must be done. Women and their families should be told early about this possible delay.

<table>
<thead>
<tr>
<th><strong>Birth partners</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Women should be supported and encouraged to have a birth partner present with them during their labour and birth. Having a trusted birth partner present throughout labour and birth is known to make a significant difference to the safety and wellbeing of women in childbirth.</td>
</tr>
<tr>
<td>At a minimum, one asymptomatic birth partner should be permitted to stay with the woman through labour and birth, unless the birth occurs under general anaesthetic.</td>
</tr>
<tr>
<td>When a woman contacts the maternity unit in early labour, she should be asked whether she or her birth partner have had any symptoms which could suggest COVID-19 in the preceding 10 days. If her partner has had onset of symptoms in the last 10 days, and has not had a negative test, the woman should be advised that her partner should not attend the unit with her and she should consider bringing another birth partner who is symptom-free. Explain the need to protect maternity staff and other women and families from the risk of infection.</td>
</tr>
<tr>
<td>On attendance to the maternity unit, all birth partners should also be asked whether they have had any symptoms that could suggest COVID-19 in the preceding 10 days. If the onset of these symptoms was within the last 10 days, and they have not had a negative test, or symptoms are still present (other than persistent cough), they should be asked to leave the maternity unit immediately and self-isolate at home. Birth partners should be asked to remain by the woman’s bedside, to not walk around the ward/hospital and to wash their hands frequently.</td>
</tr>
<tr>
<td>We recommend that birth partners be given clear advance guidance on what is expected of them should they need to accompany the woman to the operating theatre, e.g. for caesarean birth. This is particularly important given the challenges of staff communication when wearing full PPE. Restrictions on other visitors should follow hospital policy.</td>
</tr>
<tr>
<td>Respect and consent</td>
</tr>
<tr>
<td>---------------------</td>
</tr>
</tbody>
</table>
| Fetal surveillance  | Discuss with women the options for fetal surveillance in labour in accordance with existing NICE guidelines.  
Recommend CEFM for women who are symptomatic of COVID-19.  
Current infection with SARS-CoV-2 is not a contraindication for application of a fetal scalp electrode or for fetal blood sampling. |
| Pain relief         | There is no evidence that epidural or spinal analgesia or anaesthesia is contraindicated in the presence of coronaviruses.  
Epidural analgesia should therefore be recommended in labour to women with suspected or confirmed COVID-19 to minimise the need for general anaesthesia if urgent intervention for birth is needed  
Entonox should be used with a single-patient microbiological filter. This is standard issue throughout maternity units in the UK.  
There is no evidence that the use of Entonox is an aerosol-generating procedure. |
| Intrapartum care    | When a woman with confirmed or suspected COVID-19 is admitted to the maternity suite, the following members of the multidisciplinary team should be informed: consultant obstetrician, consultant anaesthetist, midwife-in-charge, consultant neonatologist, neonatal nurse-in-charge, and the infection control team.  
Maternal observations and assessment should be continued as per standard practice, with the addition of hourly oxygen saturations.  
Aim to keep oxygen saturation above 94%, titrating oxygen therapy accordingly.  
If the woman develops a fever, investigate and treat as per RCOG guidance on sepsis in pregnancy, but also consider active COVID-19 as a cause of sepsis and investigate according to Public Health England (PHE) guidance.  
Apply caution with intravenous fluid management. Given the association of COVID-19 with acute respiratory distress syndrome, women with moderate-to-severe symptoms of COVID-19 should be monitored using hourly fluid input/output charts.  
Efforts should be targeted towards achieving neutral fluid balance in labour, in order to avoid the risk of fluid overload. |
Appendix III: Full description of guidance development methods

The development methods have evolved over the lifetime of this guidance. This version of the guidance was developed by a multidisciplinary group of authors listed in acknowledgments. Specific sections of the guidance were contributed by subject experts also listed in acknowledgments.

Weekly literature reviews are generated using the following search terms, MESH headings and associated synonyms: pregnancy, coronavirus, SARS, severe acute respiratory syndrome, infant, newborn and breastfeeding. The search results are published weekly on the RCOG website.159 Populations of interest include pregnant women, those recently given birth, partners, neonates. Studies of other populations are included where necessary, in order to understand population risk, asymptomatic carriage of coronavirus and antibody results where we believe these findings can be extrapolated to pregnant women. The retrieved evidence is reviewed by clinically trained members of the guidance team for inclusion. The criteria for including evidence has evolved as the evidence base has matured. For each section of the guidance, the best available evidence is included. The guidance also includes reference to ‘grey’ literature such as registry studies, reports from national organisations and non-peer reviewed content. Where there is a need to change practice and where published alternatives are not available, ‘preprints’ are discussed within the core guidance team and considered for inclusion.

For this guidance, good practice points are based on expert consensus of the multidisciplinary guidance group comprising healthcare providers across a variety of disciplines reviewing the available evidence and from their own expertise and experience within clinical practice. Appreciating the paucity of high-quality evidence in this area, this guidance is reviewed regularly to ensure the advice remains up-to-date and relevant.

While this document has not been subject to an open peer review or formal stakeholder consultation process, specific individuals and groups were asked to review its content prior to publication. These are listed in acknowledgments and include a wide range of external stakeholders including lay representatives, other Royal Colleges and professional associations and representatives from the governments across England and the devolved nations. Feedback on this guidance sent to the dedicated COVID-19 inbox is also considered.

No external funding was received in order to develop this guidance.
Appendix IV: Key studies summary on the effect of COVID-19 on pregnancy and maternal outcomes

Tables 1 and 2 give details of the key studies on which sections 1.5.2 and 1.5.3 are based. The largest study is the PregCOV-19 systematic review. Publications already included in that systematic review are not listed individually; only the PregCOV-19 systematic review and studies that were published since that review are shown in these tables.

Table 1: Summary of key studies relevant for the effect of COVID-19 on pregnancy outcomes

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Population</th>
<th>Effect of COVID-19 on Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allotey et al 2020</td>
<td>30 Countries</td>
<td>64,676 pregnant women admitted to hospital for any reason</td>
<td>• 17% preterm birth (6% spontaneous preterm birth + 11% iatrogenic</td>
</tr>
<tr>
<td>PregCOV-19 Systematic</td>
<td></td>
<td></td>
<td>preterm birth)</td>
</tr>
<tr>
<td>Review (updated 29/11/20)</td>
<td>13</td>
<td></td>
<td>• 54% caesarean section</td>
</tr>
<tr>
<td>(PAN-COVID and AAP SONPM)</td>
<td>principally</td>
<td>COVID, 955 suspected COVID-19)</td>
<td>• 16.5% preterm birth (AAP SONPM)</td>
</tr>
<tr>
<td></td>
<td>UK</td>
<td>AAP SONPM: 2398 pregnant women with COVID-19 around the time of birth</td>
<td>• 47.9% caesarean section (PAN-COVID, confirmed COVID-19)</td>
</tr>
<tr>
<td></td>
<td>USA</td>
<td></td>
<td>• 38.2% caesarean section (AAP SONPM)</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>COVID-19:</td>
<td>Control:</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------</td>
<td>-----------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Covid-19 in pregnancy et al 2021 UKOSS update</td>
<td>UK</td>
<td>1,148 pregnant women with COVID-19 hospitalised for any reason (722 symptomatic)</td>
<td>Historical control of 694 pregnant women from 2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jering et al 2021</td>
<td>USA</td>
<td>6,380 pregnant women with COVID</td>
<td>400,066 pregnant women without COVID</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 2: Summary of key studies relevant for the effect of COVID-19 on maternal outcomes

<table>
<thead>
<tr>
<th>Study</th>
<th>Country Description</th>
<th>Population</th>
<th>Effect of COVID-19 on Pregnant Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allotey et al 2020</td>
<td>30 Countries</td>
<td>64,676 pregnant women admitted to hospital for any reason</td>
<td>- 10% severe COVID&lt;br&gt;- 4% ICU&lt;br&gt;- 3% invasive ventilation&lt;br&gt;- 0.02% death</td>
</tr>
<tr>
<td>PregCOV-19 Systematic Review (updated 29/11/20) 13</td>
<td>PAN-COVID: principally UK&lt;br&gt;AAP SONPM: USA</td>
<td>PAN-COVID: 1606 pregnant women with COVID-19 at any gestation (651 confirmed COVID, 955 suspected COVID-19)&lt;br&gt;AAP SONPM: 2398 pregnant women with COVID-19 around the time of birth</td>
<td>- 0.46% death (PAN-COVID, confirmed COVID-19)&lt;br&gt;- 0.21% death (AAP SONPM)</td>
</tr>
<tr>
<td>Mullins et al 2020</td>
<td>England, Wales, Northern Ireland</td>
<td>Pregnant: 83 pregnant women with COVID-19 and 59 recently pregnant (&lt;6 weeks) with COVID-19</td>
<td>- 12% of women of reproductive age admitted to ICU were pregnant or within 6 weeks postpartum&lt;br&gt;- for comparison the annual conception rate in UK is 7.5% of women aged 15–44</td>
</tr>
<tr>
<td>ICNARC, January 2021</td>
<td>UK</td>
<td>Control: Historical control of 694 pregnant women from 2018</td>
<td>- 5% ICU&lt;br&gt;- 9% ICU for symptomatic women&lt;br&gt;- 0.53% death</td>
</tr>
<tr>
<td>Covid-19 in pregnancy et al 2021</td>
<td>UK</td>
<td>Control: &lt;1% ICU</td>
<td></td>
</tr>
<tr>
<td>UKOSS update 24</td>
<td>UK</td>
<td>COVID-19: 1148 pregnant women with COVID-19 hospitalised for any reason (722 symptomatic)</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Group 1</td>
<td>Group 2</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Jering et al 2021</td>
<td>USA</td>
<td>COVID-19: 6,380 pregnant women with COVID</td>
<td>Control: 400,066 pregnant women without COVID</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Martinez-Portilla et al 2020</td>
<td>Mexico</td>
<td>Pregnant: 5,183 pregnant women with symptomatic COVID-19 admitted to hospital</td>
<td>Not Pregnant: 5,183 matched non-pregnant women aged 15–49 with symptomatic COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DeBolt et al 2020</td>
<td>USA</td>
<td>Pregnant: 38 pregnant women with severe or critical COVID-19</td>
<td>Not Pregnant: 94 non-pregnant women aged 23–50 with severe or critical COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Location</td>
<td>Pregnant:</td>
<td>Not Pregnant:</td>
</tr>
<tr>
<td>---------------</td>
<td>----------</td>
<td>-----------</td>
<td>--------------</td>
</tr>
<tr>
<td>Badr et al 2020</td>
<td>France</td>
<td>83 pregnant women (&gt;20 weeks) with COVID-19</td>
<td>107 non-pregnant women of reproductive age with COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oakes et al 2021</td>
<td>USA</td>
<td>22 pregnant women with symptomatic COVID-19</td>
<td>240 non-pregnant women aged 13–45 with symptomatic COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lokken et al 2021</td>
<td>USA</td>
<td>240 women with COVID-19</td>
<td>34902 adults (male and female) aged 20–39</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix V: Example of a telephone triage tool for symptomatic women with suspected or confirmed COVID-19
(adapted from Guy’s and St Thomas’ NHS Foundation Trust)

Assess severity of illness:
- Shortness of breath/difficulty breathing
- Difficulty completing short sentences without needing to stop/gasp for air
- Coughing blood
- Pain or pressure in chest (other than with coughing)
- Unable to keep liquids down
- Less responsive than normal or becoming confused while talking

None of these symptoms

Assess clinical and social risks:
- Age >35 years old, BMI >30 kg/m²
- Women of the BAME community
- Consider VTE risk assessment and score
- Medical co-morbidities: diabetes, hypertension, asthma/respiratory disease, HIV, heart disease, immunosuppression, chronic kidney disease
- Obstetric factors: at risk of fetal growth restriction, suspected preterm labour, reduced fetal movements
- Social factors: language barriers, safeguarding concerns, mental health issues, poor social support, domestic violence

No risk factors

Advise to self-isolate and arrange a COVID-19 test (if not yet done) in line with national guidance:
- Inform named consultant and midwifery team
- Safety net to call back if symptoms worsen

<table>
<thead>
<tr>
<th>Symptoms present</th>
<th>RECOMMEND ATTENDANCE FOR MATERNITY ASSESSMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk factors present</td>
<td>DISCUSS WITH CONSULTANT ABOUT POSSIBLE NEED FOR ADMISSION</td>
</tr>
</tbody>
</table>
### Appendix VI: Example of a maternity escalation plan for women with suspected or confirmed COVID-19
(adapted from Guy’s and St Thomas’ NHS Foundation Trust)

<table>
<thead>
<tr>
<th>Category</th>
<th>Clinical criteria for oxygenation</th>
<th>Suggested actions</th>
<th>Other considerations for viable fetus</th>
</tr>
</thead>
</table>
| **Green** | SpO₂ 94%–98% Room air and RR ≤ 20 | Ensure no obstetric or medical concerns  
Ensure no obstetric or medical concerns  
Discharge for self-isolation in line with national guidance | |
| **Yellow** | Target SpO₂ 94%–98% on ≥ FiO₂ 28% and/or RR ≥ 21 | Increase oxygen flow rate to maintain SaO₂ 94%–98%  
Assessment by obstetric registrar  
In-patient care  
Inform maternity escalation team:  
• Obstetric consultant  
• Obstetric anaesthetist  
• On-call medical team  
Give oral prednisolone 40 mg for treatment of COVID-19  
Assess fetal wellbeing  
Consider fetal monitoring  
Discuss timing of birth  
Depending on the gestational age:  
• Consider steroids for fetal lungs  
• Consider magnesium sulfate for neuroprotection if considering birth of the baby | |
| **Amber** | Target SpO₂ 94%–98% on ≥ FiO₂ 35% and/or RR ≥ 25 | Increase oxygen flow rate to maintain SaO₂ 94%–98%  
Consider 15l/min O₂ via non-rebreath mask  
Refer to ITU team  
Urgent review by the maternity escalation team  
Consider awake proning position when feasible/high flow oxygen in critical care setting only  
Discuss the risks and benefits of emergency caesarean birth  
Depending on the gestational age:  
• Consider steroids for fetal lungs  
• Consider magnesium sulfate for neuroprotection if considering birth | |
| **Red** | SpO₂ < 94% on 15l/min O₂ via non-rebreath mask | Urgent review by ITU team  
Urgent attendance by the maternity escalation team  
Consider awake proning position when feasible/high flow oxygen in critical care setting only  
Discuss the risks and benefits of emergency caesarean birth  
Depending on the gestational age:  
• Consider steroids for fetal lungs  
• Consider magnesium sulfate for neuroprotection if considering birth | |
| Peri-arrest | | Call 2222 – adult cardiac arrest team, obstetric crash team and neonatal crash team | |

---

84
References
References


peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/articles/provisionalbirthsi

53. Yan H, Ding Y, Guo W. Mental health of pregnant and postpartum women during the
coronavirus disease 2019 pandemic: a systematic review and meta-analysis. Front Psychol
2020;11:617001.


government/publications/staying-alert-and-safe-social-distancing/staying-alert-and-safe-social-


inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and

58. National Institute for Health and Care Excellence. Antenatal Care for Uncomplicated
Pregnancies. NICE Clinical Guideline 62 [CG62]. NICE; 2008

59. Reale SC, Fields KG, Lumbreras-Marquez MI, et al. Association Between Number of In-
Person Health Care Visits and SARS-CoV-2 Infection in Obstetrical Patients. JAMA

appointments for high risk obstetrical patients during the COVID-19 Pandemic. Am J Obstet
Gynecol MFM 2020:100233.

61. NHS England. Clinical guide for the management of remote consultations and remote working
england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/C0044-Specialty-Guide-

62. Peahl AF, Smith RD, Moniz MH. Prenatal care redesign: creating flexible maternity care models

63. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from
preconception to the postnatal period. NICE Clinical Guideline 3 [CG3]. NICE; 2015.

64. van-de-l’Isle Y, Steer PJ, Watt Coote I, et al. Impact of changes to national UK Guidance on
testing for gestational diabetes screening during a pandemic: a single centre observational

65. McIntyre HD, Gibbons KS, Ma RCW, et al. Testing for gestational diabetes during the
COVID-19 pandemic. An evaluation of proposed protocols for the United Kingdom, Canada


80. Institute for Fiscal Studies. The mental health effects of the first two months of lockdown and social distancing during the Covid-19 pandemic in the UK 2020 [https://www ifs.org.uk/


DISCLAIMER: The Royal College of Obstetricians and Gynaecologists (RCOG) has produced this guidance as an aid to good clinical practice and clinical decision-making. This guidance is based on the best evidence available at the time of writing, and the guidance will be kept under regular review as new evidence emerges. This guidance is not intended to replace clinical diagnostics, procedures or treatment plans made by a clinician or other healthcare professional and RCOG accepts no liability for the use of its guidance in a clinical setting. Please be aware that the evidence base for COVID-19 and its impact on pregnancy and related healthcare services is developing rapidly and the latest data or best practice may not yet be incorporated into the current version of this document. RCOG recommends that any departures from local clinical protocols or guidelines should be fully documented in the patient’s case notes at the time the relevant decision is taken.